<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:48:44Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10698253" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10698253</identifier>
        <datestamp>2023-12-07</datestamp>
        <setSpec>bloodadv</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article" dtd-version="1.3">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Blood Adv</journal-id>
              <journal-id journal-id-type="iso-abbrev">Blood Adv</journal-id>
              <journal-title-group>
                <journal-title>Blood Advances</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">2473-9529</issn>
              <issn pub-type="epub">2473-9537</issn>
              <publisher>
                <publisher-name>The American Society of Hematology</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10698253</article-id>
              <article-id pub-id-type="pmcid">PMC10698253</article-id>
              <article-id pub-id-type="pmc-uid">10698253</article-id>
              <article-id pub-id-type="pmid">37738155</article-id>
              <article-id pub-id-type="pii">S2473-9529(23)00527-X</article-id>
              <article-id pub-id-type="doi">10.1182/bloodadvances.2023010670</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Red Cells, Iron, and Erythropoiesis</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A multilevel mHealth intervention boosts adherence to hydroxyurea in individuals with sickle cell disease</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" id="au1">
                  <name>
                    <surname>Hankins</surname>
                    <given-names>Jane S.</given-names>
                  </name>
                  <email>jane.hankins@stjude.org</email>
                  <xref rid="aff1" ref-type="aff">1</xref>
                  <xref rid="aff2" ref-type="aff">2</xref>
                  <xref rid="aff3" ref-type="aff">3</xref>
                  <xref rid="cor1" ref-type="corresp">∗</xref>
                </contrib>
                <contrib contrib-type="author" id="au2">
                  <name>
                    <surname>Brambilla</surname>
                    <given-names>Donald</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author" id="au3">
                  <name>
                    <surname>Potter</surname>
                    <given-names>Michael B.</given-names>
                  </name>
                  <xref rid="aff5" ref-type="aff">5</xref>
                </contrib>
                <contrib contrib-type="author" id="au4">
                  <name>
                    <surname>Kutlar</surname>
                    <given-names>Abdullah</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author" id="au5">
                  <name>
                    <surname>Gibson</surname>
                    <given-names>Robert</given-names>
                  </name>
                  <xref rid="aff6" ref-type="aff">6</xref>
                </contrib>
                <contrib contrib-type="author" id="au6">
                  <name>
                    <surname>King</surname>
                    <given-names>Allison A.</given-names>
                  </name>
                  <xref rid="aff7" ref-type="aff">7</xref>
                  <xref rid="aff8" ref-type="aff">8</xref>
                </contrib>
                <contrib contrib-type="author" id="au7">
                  <name>
                    <surname>Baumann</surname>
                    <given-names>Ana A.</given-names>
                  </name>
                  <xref rid="aff8" ref-type="aff">8</xref>
                </contrib>
                <contrib contrib-type="author" id="au8">
                  <name>
                    <surname>Melvin</surname>
                    <given-names>Cathy</given-names>
                  </name>
                  <xref rid="aff9" ref-type="aff">9</xref>
                </contrib>
                <contrib contrib-type="author" id="au9">
                  <name>
                    <surname>Gordeuk</surname>
                    <given-names>Victor R.</given-names>
                  </name>
                  <xref rid="aff10" ref-type="aff">10</xref>
                </contrib>
                <contrib contrib-type="author" id="au10">
                  <name>
                    <surname>Hsu</surname>
                    <given-names>Lewis L.</given-names>
                  </name>
                  <xref rid="aff10" ref-type="aff">10</xref>
                </contrib>
                <contrib contrib-type="author" id="au11">
                  <name>
                    <surname>Nwosu</surname>
                    <given-names>Chinonyelum</given-names>
                  </name>
                  <xref rid="aff3" ref-type="aff">3</xref>
                </contrib>
                <contrib contrib-type="author" id="au12">
                  <name>
                    <surname>Porter</surname>
                    <given-names>Jerlym S.</given-names>
                  </name>
                  <xref rid="aff11" ref-type="aff">11</xref>
                </contrib>
                <contrib contrib-type="author" id="au13">
                  <name>
                    <surname>Alberts</surname>
                    <given-names>Nicole M.</given-names>
                  </name>
                  <xref rid="aff12" ref-type="aff">12</xref>
                </contrib>
                <contrib contrib-type="author" id="au14">
                  <name>
                    <surname>Badawy</surname>
                    <given-names>Sherif M.</given-names>
                  </name>
                  <xref rid="aff13" ref-type="aff">13</xref>
                  <xref rid="aff14" ref-type="aff">14</xref>
                </contrib>
                <contrib contrib-type="author" id="au15">
                  <name>
                    <surname>Simon</surname>
                    <given-names>Jena</given-names>
                  </name>
                  <xref rid="aff15" ref-type="aff">15</xref>
                </contrib>
                <contrib contrib-type="author" id="au16">
                  <name>
                    <surname>Glassberg</surname>
                    <given-names>Jeffrey A.</given-names>
                  </name>
                  <xref rid="aff15" ref-type="aff">15</xref>
                </contrib>
                <contrib contrib-type="author" id="au17">
                  <name>
                    <surname>Lottenberg</surname>
                    <given-names>Richard</given-names>
                  </name>
                  <xref rid="aff16" ref-type="aff">16</xref>
                </contrib>
                <contrib contrib-type="author" id="au18">
                  <name>
                    <surname>DiMartino</surname>
                    <given-names>Lisa</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author" id="au19">
                  <name>
                    <surname>Jacobs</surname>
                    <given-names>Sara</given-names>
                  </name>
                  <xref rid="aff4" ref-type="aff">4</xref>
                </contrib>
                <contrib contrib-type="author" id="au20">
                  <name>
                    <surname>Fernandez</surname>
                    <given-names>Maria E.</given-names>
                  </name>
                  <xref rid="aff17" ref-type="aff">17</xref>
                </contrib>
                <contrib contrib-type="author" id="au21">
                  <name>
                    <surname>Bosworth</surname>
                    <given-names>Hayden B.</given-names>
                  </name>
                  <xref rid="aff18" ref-type="aff">18</xref>
                  <xref rid="aff19" ref-type="aff">19</xref>
                </contrib>
                <contrib contrib-type="author" id="au22">
                  <name>
                    <surname>Klesges</surname>
                    <given-names>Lisa M.</given-names>
                  </name>
                  <xref rid="aff8" ref-type="aff">8</xref>
                </contrib>
                <contrib contrib-type="author" id="au23">
                  <name>
                    <surname>Shah</surname>
                    <given-names>Nirmish</given-names>
                  </name>
                  <xref rid="aff20" ref-type="aff">20</xref>
                </contrib>
                <contrib contrib-type="author">
                  <collab>Sickle Cell Disease Implementation Consortium<contrib-group><contrib contrib-type="author" id="au24"><name><surname>Hankins</surname><given-names>Jane S.</given-names></name></contrib><contrib contrib-type="author" id="au25"><name><surname>Hodges</surname><given-names>Jason</given-names></name></contrib><contrib contrib-type="author" id="au26"><name><surname>Carroll</surname><given-names>Yvonne</given-names></name></contrib><contrib contrib-type="author" id="au27"><name><surname>Klesges</surname><given-names>Lisa</given-names></name></contrib><contrib contrib-type="author" id="au28"><name><surname>Khan</surname><given-names>Hamda</given-names></name></contrib><contrib contrib-type="author" id="au29"><name><surname>Smeltzer</surname><given-names>Matthew</given-names></name></contrib><contrib contrib-type="author" id="au30"><name><surname>Nwosu</surname><given-names>Chinonyelum</given-names></name></contrib><contrib contrib-type="author" id="au31"><name><surname>Gurney</surname><given-names>James</given-names></name></contrib><contrib contrib-type="author" id="au32"><name><surname>Porter</surname><given-names>Jerlym</given-names></name></contrib><contrib contrib-type="author" id="au33"><name><surname>Alberts</surname><given-names>Nicole</given-names></name></contrib><contrib contrib-type="author" id="au34"><name><surname>French</surname><given-names>Reginald</given-names></name></contrib><contrib contrib-type="author" id="au35"><name><surname>Badawy</surname><given-names>Sherif</given-names></name></contrib><contrib contrib-type="author" id="au36"><name><surname>DeBaun</surname><given-names>Michael</given-names></name></contrib><contrib contrib-type="author" id="au37"><name><surname>Kang</surname><given-names>Guolian</given-names></name></contrib><contrib contrib-type="author" id="au38"><name><surname>Estepp</surname><given-names>Jeremie</given-names></name></contrib><contrib contrib-type="author" id="au39"><name><surname>Wang</surname><given-names>Winfred</given-names></name></contrib><contrib contrib-type="author" id="au40"><name><surname>Owens</surname><given-names>Curtis</given-names></name></contrib><contrib contrib-type="author" id="au41"><name><surname>Debon</surname><given-names>Margaret</given-names></name></contrib><contrib contrib-type="author" id="au42"><name><surname>Osarogiagbon</surname><given-names>Ray</given-names></name></contrib><contrib contrib-type="author" id="au43"><name><surname>Nelson</surname><given-names>Marquita</given-names></name></contrib><contrib contrib-type="author" id="au44"><name><surname>Treadwell</surname><given-names>Marsha</given-names></name></contrib><contrib contrib-type="author" id="au45"><name><surname>Vichinsky</surname><given-names>Elliott</given-names></name></contrib><contrib contrib-type="author" id="au46"><name><surname>Wun</surname><given-names>Ted</given-names></name></contrib><contrib contrib-type="author" id="au47"><name><surname>Potter</surname><given-names>Michael</given-names></name></contrib><contrib contrib-type="author" id="au48"><name><surname>Hessler</surname><given-names>Danielle</given-names></name></contrib><contrib contrib-type="author" id="au49"><name><surname>Hagar</surname><given-names>Ward</given-names></name></contrib><contrib contrib-type="author" id="au50"><name><surname>Marsh</surname><given-names>Anne</given-names></name></contrib><contrib contrib-type="author" id="au51"><name><surname>Neumayr</surname><given-names>Lynne</given-names></name></contrib><contrib contrib-type="author" id="au52"><name><surname>Melvin</surname><given-names>Cathy</given-names></name></contrib><contrib contrib-type="author" id="au53"><name><surname>Kanter</surname><given-names>Julie</given-names></name></contrib><contrib contrib-type="author" id="au54"><name><surname>Phillips</surname><given-names>Shannon</given-names></name></contrib><contrib contrib-type="author" id="au55"><name><surname>Adams</surname><given-names>Robert</given-names></name></contrib><contrib contrib-type="author" id="au56"><name><surname>Mueller</surname><given-names>Martina</given-names></name></contrib><contrib contrib-type="author" id="au57"><name><surname>Abrams</surname><given-names>Tina</given-names></name></contrib><contrib contrib-type="author" id="au58"><name><surname>Davia</surname><given-names>Nathalia</given-names></name></contrib><contrib contrib-type="author" id="au59"><name><surname>Shah</surname><given-names>Nirmish</given-names></name></contrib><contrib contrib-type="author" id="au60"><name><surname>Tanabe</surname><given-names>Paula</given-names></name></contrib><contrib contrib-type="author" id="au61"><name><surname>Bosworth</surname><given-names>Hayden</given-names></name></contrib><contrib contrib-type="author" id="au62"><name><surname>Jackson</surname><given-names>George</given-names></name></contrib><contrib contrib-type="author" id="au63"><name><surname>Johnson</surname><given-names>Fred</given-names></name></contrib><contrib contrib-type="author" id="au64"><name><surname>Richesson</surname><given-names>Rachel</given-names></name></contrib><contrib contrib-type="author" id="au65"><name><surname>Prvu-Bettger</surname><given-names>Janet</given-names></name></contrib><contrib contrib-type="author" id="au66"><name><surname>King</surname><given-names>Allison</given-names></name></contrib><contrib contrib-type="author" id="au67"><name><surname>Baumann</surname><given-names>Ana</given-names></name></contrib><contrib contrib-type="author" id="au68"><name><surname>Calhoun</surname><given-names>Cecilia</given-names></name></contrib><contrib contrib-type="author" id="au69"><name><surname>Kutlar</surname><given-names>Abdullah</given-names></name></contrib><contrib contrib-type="author" id="au70"><name><surname>Gibson</surname><given-names>Robert</given-names></name></contrib><contrib contrib-type="author" id="au71"><name><surname>Snyder</surname><given-names>Angie</given-names></name></contrib><contrib contrib-type="author" id="au72"><name><surname>Fernandez</surname><given-names>Maria</given-names></name></contrib><contrib contrib-type="author" id="au73"><name><surname>Lottenberg</surname><given-names>Richard</given-names></name></contrib><contrib contrib-type="author" id="au74"><name><surname>Richardson</surname><given-names>Lynne D.</given-names></name></contrib><contrib contrib-type="author" id="au75"><name><surname>Glassberg</surname><given-names>Jeffrey</given-names></name></contrib><contrib contrib-type="author" id="au76"><name><surname>Simon</surname><given-names>Jena</given-names></name></contrib><contrib contrib-type="author" id="au77"><name><surname>Genes</surname><given-names>Nicholas G.</given-names></name></contrib><contrib contrib-type="author" id="au78"><name><surname>Loo</surname><given-names>George T.</given-names></name></contrib><contrib contrib-type="author" id="au79"><name><surname>Shapiro</surname><given-names>Jason S.</given-names></name></contrib><contrib contrib-type="author" id="au80"><name><surname>Souffront</surname><given-names>Kimberly</given-names></name></contrib><contrib contrib-type="author" id="au81"><name><surname>Clesca</surname><given-names>Cindy</given-names></name></contrib><contrib contrib-type="author" id="au82"><name><surname>Linton</surname><given-names>Elizabeth</given-names></name></contrib><contrib contrib-type="author" id="au83"><name><surname>Ryan</surname><given-names>Gery</given-names></name></contrib><contrib contrib-type="author" id="au84"><name><surname>Kroner</surname><given-names>Barbara L</given-names></name></contrib><contrib contrib-type="author" id="au85"><name><surname>Hendershot</surname><given-names>Tabitha</given-names></name></contrib><contrib contrib-type="author" id="au86"><name><surname>DiMartino</surname><given-names>Lisa</given-names></name></contrib><contrib contrib-type="author" id="au87"><name><surname>Jacobs</surname><given-names>Sara</given-names></name></contrib><contrib contrib-type="author" id="au88"><name><surname>Battestilli</surname><given-names>Whitney</given-names></name></contrib><contrib contrib-type="author" id="au89"><name><surname>Brambilla</surname><given-names>Donald</given-names></name></contrib><contrib contrib-type="author" id="au90"><name><surname>Cox</surname><given-names>Lisa</given-names></name></contrib><contrib contrib-type="author" id="au91"><name><surname>Preiss</surname><given-names>Liliana</given-names></name></contrib><contrib contrib-type="author" id="au92"><name><surname>Pugh</surname><given-names>Norma</given-names></name></contrib><contrib contrib-type="author" id="au93"><name><surname>Li</surname><given-names>Sophie</given-names></name></contrib><contrib contrib-type="author" id="au94"><name><surname>VonLehmden</surname><given-names>Annie</given-names></name></contrib><contrib contrib-type="author" id="au95"><name><surname>Smith</surname><given-names>Sharon M</given-names></name></contrib><contrib contrib-type="author" id="au96"><name><surname>Tonkins</surname><given-names>William P.</given-names></name></contrib><contrib contrib-type="author" id="au97"><name><surname>Peters-Lawrence</surname><given-names>Marlene</given-names></name></contrib><contrib contrib-type="author" id="au98"><name><surname>Boyce</surname><given-names>Cheryl</given-names></name></contrib><contrib contrib-type="author" id="au99"><name><surname>Barfield</surname><given-names>Whitney</given-names></name></contrib><contrib contrib-type="author" id="au100"><name><surname>Thompson</surname><given-names>Alexis</given-names></name></contrib><contrib contrib-type="author" id="au101"><name><surname>Gordeuk</surname><given-names>Victor</given-names></name></contrib><contrib contrib-type="author" id="au102"><name><surname>Gutierrez</surname><given-names>Melissa</given-names></name></contrib><contrib contrib-type="author" id="au103"><name><surname>Hirschtick</surname><given-names>Jana</given-names></name></contrib><contrib contrib-type="author" id="au104"><name><surname>Hsu</surname><given-names>Lewis</given-names></name></contrib><contrib contrib-type="author" id="au105"><name><surname>Krishnan</surname><given-names>Jerry</given-names></name></contrib><contrib contrib-type="author" id="au106"><name><surname>Sebro</surname><given-names>Nadew</given-names></name></contrib><contrib contrib-type="author" id="au107"><name><surname>Verda</surname><given-names>Larissa</given-names></name></contrib><contrib contrib-type="author" id="au108"><name><surname>Wandersman</surname><given-names>Abe</given-names></name></contrib><contrib contrib-type="author" id="au109"><name><surname>Berbaum</surname><given-names>Michael</given-names></name></contrib><contrib contrib-type="author" id="au110"><name><surname>Bobba</surname><given-names>Kishore</given-names></name></contrib><contrib contrib-type="author" id="au111"><name><surname>Colla</surname><given-names>Joe</given-names></name></contrib><contrib contrib-type="author" id="au112"><name><surname>Erwin</surname><given-names>Kim</given-names></name></contrib><contrib contrib-type="author" id="au113"><name><surname>Lamont</surname><given-names>Andrea</given-names></name></contrib><contrib contrib-type="author" id="au114"><name><surname>Martin</surname><given-names>Molly</given-names></name></contrib><contrib contrib-type="author" id="au115"><name><surname>Norell</surname><given-names>Sarah</given-names></name></contrib><contrib contrib-type="author" id="au116"><name><surname>Pandit</surname><given-names>Ananta</given-names></name></contrib><contrib contrib-type="author" id="au117"><name><surname>Saving</surname><given-names>Kay</given-names></name></contrib><contrib contrib-type="author" id="au118"><name><surname>Shannon</surname><given-names>Robin</given-names></name></contrib><contrib contrib-type="author" id="au119"><name><surname>Winn</surname><given-names>Robert</given-names></name></contrib><contrib contrib-type="author" id="au120"><name><surname>Zun</surname><given-names>Leslie</given-names></name></contrib><contrib contrib-type="author" id="au121"><name><surname>Hassan</surname><given-names>Taif</given-names></name></contrib><contrib contrib-type="author" id="au122"><name><surname>Lasley</surname><given-names>Patricia</given-names></name></contrib><contrib contrib-type="author" id="au123"><name><surname>Monnard</surname><given-names>Kristin</given-names></name></contrib><contrib contrib-type="author" id="au124"><name><surname>Nocek</surname><given-names>Judith</given-names></name></contrib><contrib contrib-type="author" id="au125"><name><surname>Roesch</surname><given-names>Pamela</given-names></name></contrib></contrib-group></collab>
                </contrib>
                <aff id="aff1"><label>1</label>Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN</aff>
                <aff id="aff2"><label>2</label>Center for Sickle Cell Disease, University of Tennessee Health Science Center, Memphis, TN</aff>
                <aff id="aff3"><label>3</label>Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN</aff>
                <aff id="aff4"><label>4</label>RTI International, Research Triangle Park, NC</aff>
                <aff id="aff5"><label>5</label>Department of Family and Community Medicine, University of California San Francisco School of Medicine, San Francisco, CA</aff>
                <aff id="aff6"><label>6</label>Center for Blood Disorders, Medical College of Georgia, Augusta University, Augusta, GA</aff>
                <aff id="aff7"><label>7</label>Department of Pediatrics, Washington University in St. Louis, St. Louis, MO</aff>
                <aff id="aff8"><label>8</label>Division of Public Health Sciences, Department of Surgery, Washington University, St. Louis, MO</aff>
                <aff id="aff9"><label>9</label>Department of Public Health Sciences, College of Medicine, Medical University of South Carolina, Charleston, SC</aff>
                <aff id="aff10"><label>10</label>Sickle Cell Center, University of Illinois at Chicago, Chicago, IL</aff>
                <aff id="aff11"><label>11</label>Department of Psychology and Biobehavioral Sciences, St. Jude Children’s Research Hospital, Memphis, TN</aff>
                <aff id="aff12"><label>12</label>Department of Psychology, Concordia University, Montreal, QC, Canada</aff>
                <aff id="aff13"><label>13</label>Division of Hematology, Oncology, and Stem Cell Transplant, Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago, IL</aff>
                <aff id="aff14"><label>14</label>Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL</aff>
                <aff id="aff15"><label>15</label>Department of Emergency Medicine, Icahn School of Medicine at Mount Sinai, New York, NY</aff>
                <aff id="aff16"><label>16</label>Department of Medicine, University of Florida, Gainesville, FL</aff>
                <aff id="aff17"><label>17</label>Health Promotion and Behavioral Sciences, School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX</aff>
                <aff id="aff18"><label>18</label>Department of Population Health Studies, Duke University, Durham, NC</aff>
                <aff id="aff19"><label>19</label>Center of Innovation to Accelerate Discovery and Practice Transformation Durham Veterans Affairs Medical Center, Durham, NC</aff>
                <aff id="aff20"><label>20</label>Department of Pediatric Hematology and Oncology, Duke University, Durham, NC</aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1"><label>∗</label>Correspondence: Jane S. Hankins, Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, 262 Danny Thomas Pl, Memphis, TN 38105; <email>jane.hankins@stjude.org</email></corresp>
              </author-notes>
              <pub-date pub-type="pmc-release">
                <day>26</day>
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.-->
              <pub-date pub-type="collection">
                <day>12</day>
                <month>12</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>26</day>
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <volume>7</volume>
              <issue>23</issue>
              <fpage>7190</fpage>
              <lpage>7201</lpage>
              <history>
                <date date-type="received">
                  <day>8</day>
                  <month>5</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>5</day>
                  <month>9</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.</copyright-statement>
                <copyright-year>2023</copyright-year>
                <copyright-holder>The American Society of Hematology</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p>
                </license>
              </permissions>
              <abstract abstract-type="author-highlights" id="abs0010">
                <title>Key Points</title>
                <p>
                  <list list-type="simple" id="ulist0010">
                    <list-item id="u0010">
                      <label>•</label>
                      <p id="p0010">Hydroxyurea adherence increased by 19.8% with a tailored mHealth intervention in people with SCD and adherence &lt;80%.</p>
                    </list-item>
                    <list-item id="u0015">
                      <label>•</label>
                      <p id="p0015">mHealth boosts hydroxyurea adherence and is associated with reduction in self-reported pain and pain admissions rate in SCD.</p>
                    </list-item>
                  </list>
                </p>
              </abstract>
              <abstract abstract-type="graphical" id="abs0015">
                <title>Visual Abstract</title>
                <p><bold>Visual abstract. Relationship between InCharge Health app use and hydroxyurea adherence.</bold> The frequency of InCharge Health app use by individuals with SCD, as measured by the percentage of days the app was used during the intervention period, was significantly associated with greater changes in hydroxyurea adherence (<italic>P</italic> &lt; .001), as measured by the PDC. Although as little as 13 days of app use was associated with significant PDC increases, patients who used the app for &gt;50% of the duration of the study (≥85 days) saw the greatest mean increase in PDC (26.9%).<fig id="undfig1" position="anchor"><graphic xlink:href="BLOODA_ADV-2023-010670-ga1"/></fig></p>
              </abstract>
              <abstract id="abs0020">
                <title>Abstract</title>
                <p>Hydroxyurea reduces sickle cell disease (SCD) complications, but medication adherence is low. We tested 2 mobile health (mHealth) interventions targeting determinants of low adherence among patients (InCharge Health) and low prescribing among providers (HU Toolbox) in a multi-center, non-randomized trial of individuals with SCD ages 15-45. We compared the percentage of days covered (PDC), labs, healthcare utilization, and self-reported pain over 24 weeks of intervention and 12 weeks post-study with a 24-week preintervention interval. We enrolled 293 patients (51% male; median age 27.5 years, 86.8% HbSS/HbSβ0-thalassemia). The mean change in PDC among 235 evaluable subjects increased (39.7% to 56.0%; <italic>P</italic> &lt; 0.001) and sustained (39.7% to 51.4%, <italic>P</italic> &lt; 0.001). Mean HbF increased (10.95% to 12.78%; <italic>P</italic> = 0.03). Self-reported pain frequency reduced (3.54 to 3.35 events/year; <italic>P</italic> = 0.041). InCharge Health was used ≥1 day by 199 of 235 participants (84.7% implementation; median usage: 17% study days; IQR: 4.8-45.8%). For individuals with ≥1 baseline admission for pain, admissions per 24 weeks declined from baseline through 24 weeks (1.97 to 1.48 events/patient, <italic>P</italic> = 0.0045) and weeks 25-36 (1.25 events/patient, <italic>P</italic> = 0.0015). PDC increased with app use (<italic>P</italic> &lt; 0.001), with the greatest effect in those with private insurance (<italic>P</italic> = 0.0078), older subjects (<italic>P</italic> = 0.033), and those with lower pain interference (<italic>P</italic> = 0.0012). Of the 89 providers (49 hematologists, 36 advanced care providers, 4 unreported), only 11.2% used HU Toolbox ≥1/month on average. This use did not affect change in PDC. Tailoring mHealth solutions to address barriers to hydroxyurea adherence can potentially improve adherence and provide clinical benefits. A definitive randomized study is warranted. This trial was registered at <ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov" id="interref0010">www.clinicaltrials.gov</ext-link> as #NCT04080167.</p>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec id="sec1">
              <title>Introduction</title>
              <p id="p0020">Hydroxyurea (hydroxycarbamide) is one of only 4 agents approved by the US Food and Drug Administration to treat individuals with sickle cell disease (SCD).<xref rid="bib1" ref-type="bibr"><sup>1</sup></xref> Hydroxyurea can reduce the frequency of acute events,<xref rid="bib2" ref-type="bibr"><sup>2</sup></xref> preserve organ function,<xref rid="bib3" ref-type="bibr"><sup>3</sup></xref> improve quality of life (QoL),<xref rid="bib4" ref-type="bibr"><sup>4</sup></xref> increase survival,<xref rid="bib5" ref-type="bibr"><sup>5</sup></xref><sup>,</sup><xref rid="bib6" ref-type="bibr"><sup>6</sup></xref> and reduce health care expenditures.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib8" ref-type="bibr"><sup>8</sup></xref> Adherence to hydroxyurea prescriptions by children and adults living with SCD is low,<xref rid="bib9" ref-type="bibr">9</xref>, <xref rid="bib10" ref-type="bibr">10</xref>, <xref rid="bib11" ref-type="bibr">11</xref> commonly &lt;80%,<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref><sup>,</sup><xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> corresponding to less clinical benefit.</p>
              <p id="p0025">Interventions to improve hydroxyurea adherence have failed to provide robust and consistent effects, either because they were not tailored to the barriers of poor adherence or because study designs did not reflect real-world contexts.<xref rid="bib14" ref-type="bibr"><sup>14</sup></xref> Adherence can be affected by both patient behavior and prescribing practices. Therefore, we conducted a literature synthesis,<xref rid="bib15" ref-type="bibr">15</xref>, <xref rid="bib16" ref-type="bibr">16</xref>, <xref rid="bib17" ref-type="bibr">17</xref>, <xref rid="bib18" ref-type="bibr">18</xref>, <xref rid="bib19" ref-type="bibr">19</xref> population-level claims analysis,<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> patient and provider surveys,<xref rid="bib20" ref-type="bibr"><sup>20</sup></xref><sup>,</sup><xref rid="bib21" ref-type="bibr"><sup>21</sup></xref> semistructured interviews, and focus groups analysis<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref><sup>,</sup><xref rid="bib23" ref-type="bibr"><sup>23</sup></xref> to identify contributors to poor patient adherence and poor provider prescribing behavior. Cognitive and behavioral factors relevant to improving patient adherence were identified from the empirical and theoretical literature, including psychosocial frameworks, such as the Health Belief Model<xref rid="bib24" ref-type="bibr"><sup>24</sup></xref> and Social Cognitive Theory.<xref rid="bib25" ref-type="bibr"><sup>25</sup></xref> Theory-informed factors associated with hydroxyurea use included high perceived disease severity, low motivation to take medications, memory deficit (leading to deficient habituation), low understanding of hydroxyurea benefit (ie, low medication knowledge), and low self-efficacy with taking hydroxyurea. Poor provider prescribing habits were associated with low hydroxyurea prescribing self-efficacy and low hydroxyurea knowledge.</p>
              <p id="p0030">Based on these findings, we designed the following two-level mobile health (mHealth) interventions: the InCharge Health app,<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> which targeted the determinants of low hydroxyurea adherence among patients, and the HU Toolbox, which targeted low hydroxyurea prescribing among providers.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> We tested the effectiveness of the combined intervention at improving hydroxyurea adherence in the multicenter SCD Implementation Consortium (SCDIC) study “Integration of mHealth into SCD Care to Increase Hydroxyurea Utilization (meSH).”<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> We tested the hypothesis that among patients with SCD aged between 15 and 45 years, a two-level mHealth intervention would promote a 12% mean absolute increase (20% relative increase) in percent days covered (PDC), which is a proxy for medication adherence.<xref rid="bib27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="bib28" ref-type="bibr"><sup>28</sup></xref></p>
            </sec>
            <sec id="sec2">
              <title>Methods</title>
              <sec id="sec2.1">
                <title>Study setting and participant selection</title>
                <p id="p0035">The SCDIC was funded by the National Heart Lung and Blood Institute (NHLBI) to develop and evaluate interventions and implementation strategies to bolster patient use and provider adoption of evidence-based therapies for SCD.<xref rid="bib29" ref-type="bibr"><sup>29</sup></xref> Seven SCDIC sites (4 in the Southeast, 2 in the Midwest, and 1 in the Northeast of the United States) participated. Patients were treated at 1 to 3 academic and community clinics connected to each site, with ∼2200 children and adults with SCD receiving care at these 7 sites.</p>
                <p id="p0040">Physicians, nurse practitioners, and physician assistants who treated at least 1 patient with SCD for an anticipated minimum of 12 months after study enrollment were eligible.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> Patient participants (all nested within clinics where provider participants worked) had to have a documented SCD diagnosis, aged between 15 and 45, treated at a participating SCDIC site, English-speaking, and owned a mobile phone. They also needed to have at least 1 written hydroxyurea prescription (regardless of whether it is filled) in the 3 months before enrollment. Hydroxyurea initiation at baseline was allowed but excluded subjects from primary outcome analysis. All sites obtained study institutional review board approval, and all participants provided consent or assent before study participation.</p>
              </sec>
              <sec id="sec2.2">
                <title>Study design and intervention</title>
                <p id="p0045">meSH was a non-nonrandomized, closed cohort hybrid-effectiveness trial (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov" id="intref0015">ClinicalTrials.gov</ext-link> NCT04080167).<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref> The 7 sites were split into 3 groups which started the study at 6-month intervals. To allow time for training on study procedures, providers started using HU Toolbox 3 months before their patients were enrolled and used it for 9 months, whereas patients used InCharge Health app for 6 months. Study enrollment occurred from September 2019 to September 2021.</p>
                <p id="p0050">The InCharge Health intervention is a smartphone health app that directly targets determinants of low hydroxyurea adherence. It offers (1) daily customizable reminders; (2) daily recording of hydroxyurea adherence (click “yes” or “no” to taking hydroxyurea) and pain intensity scores; (3) pain severity vs adherence tracking; (4) communication with health care providers (via the patient portal) and other individuals with SCD; (5) educational resources about SCD and hydroxyurea; and (6) a patient-appointed accountability partner who receives daily notifications if the user has not documented the use of hydroxyurea for &gt;4 hours.<xref rid="bib22" ref-type="bibr"><sup>22</sup></xref> The HU Toolbox is a decision-support tool that contains NHLBI guidelines adapted for pediatric and adult providers, an artificial intelligence algorithm guiding clinicians on hydroxyurea prescribing and side effects monitoring through a chatbot, and a built-in feature to consult SCD experts.<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> All sites’ research and clinical staff were trained to download and use InCharge Health and HU Toolbox. Participants were instructed on how to use their designated apps only during enrollment. After enrollment, study visits occurred at weeks 12 and 24 for patients and week 36 for providers. Providers were aware of the study interventions that their patients received.</p>
              </sec>
              <sec id="sec2.3">
                <title>Outcomes</title>
                <p id="p0055">The primary outcome was a change in PDC. We compared PDC over a 24-week baseline interval that ended the day before enrollment with PDC over 24 weeks of intervention. PDC is a process measure of adherence used by the Centers for Medicare &amp; Medicaid Services reflective of real-world settings.<xref rid="bib28" ref-type="bibr"><sup>28</sup></xref><sup>,</sup><xref rid="bib30" ref-type="bibr"><sup>30</sup></xref> Baseline PDC and change in PDC were calculated only for subjects with at least 1 prescription filled before starting the baseline period. In some, but not all cases, the prebaseline prescription covered the start of the baseline period. Study coordinators collected refill data from the pharmacies where patient participants reported having filled their prescriptions or from the electronic health record.</p>
                <p id="p0060">Secondary patient outcomes included the change in mean acute care use (emergency department, ED, and hospitalization encounters) and laboratory markers of hydroxyurea effect (fetal hemoglobin [HbF], hemoglobin [Hb], mean corpuscular volume [MCV], reticulocyte percent count, absolute neutrophil count [ANC], and platelets) between the baseline period and the 24 weeks of the intervention. Validated patient-reported outcome (PRO) measures were investigated as predictors of adherence change, including the Adult Sickle Cell QoL Measurement Information System social functioning, pain impact, pain frequency, pain severity,<xref rid="bib31" ref-type="bibr">31</xref>, <xref rid="bib32" ref-type="bibr">32</xref>, <xref rid="bib33" ref-type="bibr">33</xref> the Patient-Reported Outcomes Measurement Information System pain quality,<xref rid="bib34" ref-type="bibr"><sup>34</sup></xref> self-efficacy,<xref rid="bib35" ref-type="bibr"><sup>35</sup></xref> and Neuro-QoL measures of cognitive and attention problems.<xref rid="bib36" ref-type="bibr"><sup>36</sup></xref> Pain PROs were compared between baseline and week 24. Secondary provider outcomes included a change in hydroxyurea prescribing knowledge (5-question survey about appropriate dosing and toxicity management) and self-efficacy in prescribing hydroxyurea (4-question survey confidence in prescribing) between baseline and week 36.</p>
                <p id="p0065">The RE-AIM framework evaluated the robustness of the intervention.<xref rid="bib37" ref-type="bibr"><sup>37</sup></xref> RE-AIM domains include (1) reach: proportion and representativeness of the eligible target patient population enrolled, (2) effectiveness: adherence improvement among patients and hydroxyurea prescribing knowledge and self-efficacy among providers, (3) adoption: proportion of clinics and providers approached that enrolled, (4) implementation: level of app engagement by patients and providers, (5) maintenance: continuation of effectiveness and app engagement beyond the study period (ie, through week 36).</p>
              </sec>
              <sec id="sec2.4">
                <title>Power calculation</title>
                <p id="p0070">With minimal available data regarding the variance of baseline PDC within sites, site-to-site variation in mean baseline PDC, and treatment response, simulations were based on conservative assumptions regarding variability in baseline PDC and change in PDC. We determined the sample size required to detect a mean absolute increase of 12% in PDC (20% relative increase) after the intervention (∼1 additional day of treatment weekly).<xref rid="bib26" ref-type="bibr"><sup>26</sup></xref> Initial simulations indicated that 276 subjects would provide 90% power to reject the null hypothesis of no change in PDC when the average increase in PDC was 12%. The sample size was inflated to 368 subjects to account for an expected 25% loss during the study. Actual variance components during the study were lower than initially assumed, resulting in &gt;90% power to detect an absolute increase of 12% in PDC with 235 evaluable subjects.</p>
              </sec>
              <sec id="sec2.5">
                <title>Analysis plan</title>
                <p id="p0075">The primary outcome, mean change in PDC, was evaluated using a 2-sided 1-sample <italic>t</italic>-test. A sensitivity analysis was conducted to account for missing follow-up data in which missing follow-up PDCs were conservatively set at zero.</p>
                <p id="p0080">Predictors of change in PDC included baseline PDC, site or clinic, frequency of InCharge Health app use, demographics, and baseline PROs (<xref rid="appsec1" ref-type="sec">supplemental Table 1</xref>). The frequency of InCharge Health app use was defined as the percentage of 168 days on which the app was accessed at least once. App use was treated as continuous in 1 analysis and as a 5-level categorical variable in another, with cut points producing following 5 groups of similar size: ≥50.1%, ≥21.5% but &lt;50.1%, ≥7.2% but &lt;21.5%, ≥0.6% but &lt;7.2%, and &lt;0.6%. Predictors were evaluated using linear models. Because we expected a negative correlation between baseline PDC and change in PDC, baseline PDC was included in all models. First, predictors were evaluated individually. Least square means (referred to as adjusted mean changes) were calculated to adjust for variation in the distribution of baseline PDC among levels of predictors, with the predictor treated as categorical and baseline PDC as continuous. Next, predictors that were statistically significant at the first step, plus those that were not, were considered in 2 multivariable models. Clinic was nested within the site, creating linear dependence, so 1 model included the clinic and the other site. Backward elimination reduced the models to the subset of statistically significant predictors (<italic>P</italic> &lt; .05), retaining baseline PDC and site or clinic at all steps to reduce heterogeneity. No adjustment for multiple comparisons was made, because results should be considered exploratory.</p>
                <p id="p0085">The proportions with PDC &gt;80% at baseline and follow-up were compared using McNemar test. One-sample <italic>t</italic>-tests were used to examine changes in laboratory measures. Changes in counts of ED visits and hospitalizations were assessed using Poisson regression with generalized estimating equations to account for the repeated observations on the same subjects. Associations between changes in PDC and changes in number of ED visits and hospitalizations were investigated using linear models. We used SAS software (copyright 2012-20, SAS Institute Inc) for all analyses.</p>
              </sec>
            </sec>
            <sec id="sec3">
              <title>Results</title>
              <sec id="sec3.1">
                <title>Participant characteristics and study participation</title>
                <p id="p0090">We enrolled 293 individuals with SCD. Five individuals started hydroxyurea at baseline and did not contribute to the main outcome analysis. Of the remaining 288, 21 were lost to follow-up, 3 involuntarily discontinued hydroxyurea (2 pregnancies and 1 loss of health coverage precluding financial access to medication), 2 withdrew, and 2 died (1 violent death and 1 central line–associated sepsis and multiorgan failure). The remaining 260 completed the 24 weeks of the study, yielding a study retention of 90.3%. Of those completing the 24 weeks, 11 had incomplete baseline prescription refill data (no prescription before the enrollment date), 14 changed the dispensing pharmacy during the study, and the new pharmacy information was unavailable, preventing the calculation of the 24-week PDC value. The remaining 235 had baseline and 24-week PDC data and were included in the primary analysis (<xref rid="fig1" ref-type="fig">Figure 1</xref>). Most patient participants were non-Hispanic African Americans with HbSS or HbSβ<sup>0</sup>-thalassemia (<xref rid="tbl1" ref-type="table">Table 1</xref>). A balance of males and females participated. Most had at least a high school degree and household incomes &lt;$25 000 per year. Evaluable patient participants had higher baseline PDC than unevaluable ones, and they tended to be older, female, and had slightly higher income (<xref rid="tbl2" ref-type="table">Table 2</xref>; <xref rid="appsec1" ref-type="sec">supplemental Table 2</xref>).<fig id="fig1"><label>Figure 1.</label><caption><p><bold>CONSORT diagram of patient participants. ∗</bold>Involuntary discontinuation of hydroxyurea; reasons included pregnancy or lack of drug access. ∗∗Participants were missing baseline refill data (11 patients) or 24-week refill data (14 patients) due to the inability to locate a dispensing pharmacy.</p></caption><graphic xlink:href="BLOODA_ADV-2023-010670-gr1"/></fig><table-wrap position="float" id="tbl1"><label>Table 1.</label><caption><p><bold>Baseline participants’ characteristics</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th align="center">Patients (N = 293)</th><th align="center">Providers (N = 89)</th></tr></thead><tbody><tr><td><bold>Age category (y)</bold></td><td/><td/></tr><tr><td> 15-19</td><td align="center">44 (15.02)</td><td>-</td></tr><tr><td> 20-24</td><td align="char">76 (25.94)</td><td align="center">-</td></tr><tr><td> 25-29</td><td align="char">57 (19.45)</td><td align="char">1 (1.2)</td></tr><tr><td> 30-34</td><td align="char">51 (17.41)</td><td align="char">25 (29.1)</td></tr><tr><td> 35-39</td><td align="char">33 (11.26)</td><td align="char">19 (22.1)</td></tr><tr><td> 40-45</td><td align="char">32 (10.92)</td><td align="char">9 (10.5)</td></tr><tr><td> 46-50</td><td align="center">-</td><td align="char">9 (10.5)</td></tr><tr><td> 51-55</td><td align="center">-</td><td align="char">6 (7.0)</td></tr><tr><td> 56-60</td><td align="center">-</td><td align="char">8 (9.3)</td></tr><tr><td> &gt;60</td><td align="center">-</td><td align="char">9 (10.5)</td></tr><tr><td> Missing</td><td align="center">-</td><td align="center">3</td></tr><tr><td><bold>Gender, n (%)</bold></td><td align="char">152 (51.9)</td><td align="char">65 (76.5)</td></tr><tr><td> Female</td><td/><td/></tr><tr><td> Male</td><td align="char">141 (48.1)</td><td align="char">20 (23.5)</td></tr><tr><td> Missing</td><td/><td align="center">4</td></tr><tr><td><bold>Race (n)</bold></td><td/><td/></tr><tr><td> Black</td><td align="center">283</td><td align="center">23</td></tr><tr><td> American Indian or Alaska Native</td><td align="center">2</td><td align="center">-</td></tr><tr><td> Native Hawaiian or Pacific Islander</td><td align="center">3</td><td align="center">-</td></tr><tr><td> White</td><td align="center">1</td><td align="center">45</td></tr><tr><td> Asian</td><td/><td align="center">15</td></tr><tr><td> Mixed race</td><td align="center">1</td><td align="center">3</td></tr><tr><td> Missing</td><td align="center">2</td><td align="center">3</td></tr><tr><td><bold>Ethnicity (n, %)</bold></td><td/><td/></tr><tr><td> Non-Hispanic</td><td align="char">280 (96.2)</td><td align="char">84 (96.6)</td></tr><tr><td> Hispanic</td><td align="char">11 (3.8)</td><td align="char">3 (3.5)</td></tr><tr><td> Missing</td><td align="center">2</td><td align="center">2</td></tr><tr><td><bold>SCD genotype (n, %)</bold></td><td/><td/></tr><tr><td> HbSS/HbSβ<sup>0</sup>-thalassemia</td><td align="char">248 (84.9)</td><td>-</td></tr><tr><td> HbSC/HbSβ<sup>+</sup>-thalassemia/other</td><td align="char">44 (15.1)</td><td align="center">-</td></tr><tr><td> Missing</td><td align="center">1</td><td/></tr><tr><td><bold>Education (n, %)</bold><xref rid="tbl1fnlowast" ref-type="table-fn">∗</xref></td><td/><td/></tr><tr><td> Less than high school</td><td align="char">8 (2.8)</td><td>-</td></tr><tr><td> Some high school</td><td align="char">35 (12.2)</td><td align="center">-</td></tr><tr><td> High school graduate or GED test equivalent</td><td align="char">92 (32.2)</td><td align="center">-</td></tr><tr><td> Some college or vocational training</td><td align="char">85 (29.7)</td><td align="center">-</td></tr><tr><td> College graduate</td><td align="char">44 (15.4)</td><td align="center">-</td></tr><tr><td> Some graduate school or professional school</td><td align="char">5 (1.8)</td><td align="center">-</td></tr><tr><td> Graduate or professional degree</td><td align="char">17 (5.9)</td><td align="center">-</td></tr><tr><td> Missing</td><td align="center">7</td><td align="center">-</td></tr><tr><td><bold>Annual income (n, %)</bold></td><td/><td/></tr><tr><td> ≤$25 000</td><td align="char">166 (62.2)</td><td>-</td></tr><tr><td> $25 001- $50 000</td><td align="char">60 (22.5)</td><td align="center">-</td></tr><tr><td> $50 001- $75 000</td><td align="char">19 (7.1)</td><td align="center">-</td></tr><tr><td> $75 001-$100 000</td><td align="char">11 (4.1)</td><td align="center">-</td></tr><tr><td> &gt;$100 000</td><td align="char">11 (4.1)</td><td align="center">-</td></tr><tr><td> Missing</td><td align="center">26</td><td align="center">-</td></tr><tr><td><bold>InCharge Health app usage (n, %)</bold><xref rid="tbl1fnlowast" ref-type="table-fn">∗</xref></td><td/><td/></tr><tr><td> &gt;50%</td><td align="char">49 (16.8)</td><td>-</td></tr><tr><td> ≤21.5%, &lt;50.1%</td><td align="char">52 (17.8)</td><td align="center">-</td></tr><tr><td> ≥7.2%, &lt;21.5%</td><td align="char">59 (20.2)</td><td align="center">-</td></tr><tr><td> ≥0.6%, &lt;7.2%</td><td align="char">64 (21.90)</td><td align="center">-</td></tr><tr><td> &lt;0.6%</td><td align="char">68 (23.3)</td><td/></tr><tr><td> Missing</td><td align="center">1</td><td/></tr><tr><td><bold>Provider type, n (%)</bold></td><td/><td/></tr><tr><td> Physician hematologist</td><td>-</td><td align="char">36 (40.4)</td></tr><tr><td> Physician generalist<xref rid="tbl1fndagger" ref-type="table-fn">†</xref></td><td align="center">-</td><td align="char">13 (14.6)</td></tr><tr><td> Nurse practitioner or physician assistant working in a hematology clinic</td><td/><td align="char">28 (31.5)</td></tr><tr><td> Nurse practitioner or physician assistant working in a primary care clinic</td><td align="center">-</td><td align="char">8 (9)</td></tr><tr><td> Chose not to report</td><td align="center">-</td><td align="char">4 (4.5)</td></tr><tr><td><bold>HU Toolbox app usage (n, %)</bold></td><td/><td/></tr><tr><td> ≥6 times during the study</td><td>-</td><td align="char">10 (11.2%)</td></tr><tr><td> &lt;6 times during the study</td><td align="center">-</td><td align="char">79 (88.8%)</td></tr></tbody></table><table-wrap-foot><fn><p>GED, General Educational Development.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fnlowast"><label>∗</label><p id="ntpara0015">App usage was calculated as the percentage of days of app use over the 168 days of the study.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl1fndagger"><label>†</label><p id="ntpara0020">Specialties for physician generalists included family medicine, pediatrics, and internal medicine, with &gt;80% with substantial experience in caring for individuals with SCD.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="tbl2"><label>Table 2.</label><caption><p><bold>RE-AIM evaluation measures and outcomes by intervention target</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th>RE-AIM domain</th><th align="center">Patient participants</th><th>Provider participants</th></tr></thead><tbody><tr><td>Reach</td><td>Percentage of patients enrolled in the study among all eligible patients: 293/611 (48.0%).<break/>Percentage of patients enrolled in the study among those eligible and approached: 293/343 (85.4%).<break/>Percentage of patients included in the analysis (evaluable<xref rid="tbl2fnlowast" ref-type="table-fn">∗</xref>) among all patients who enrolled but were not included in analyses (unevaluable): 235/293 (80.2%).<break/>Representativeness: evaluable participants tended to be older (median age, 28 vs 25 years), female (49% vs 64%), have HbSS/Sβ0-thal genotype (87% vs 77%), higher annual income (60% vs 74% made &lt;$25 000/year) and higher baseline PDC (39.7% vs 18.5%) than unevaluable, but did not differ in educational level or health coverage type (<xref rid="appsec1" ref-type="sec">supplemental Table 2</xref>).</td><td>Not measured</td></tr><tr><td>Effectiveness</td><td>Mean change in hydroxyurea adherence among those receiving the intervention and evaluable: 16.3% (<italic>P</italic> &lt; .0001) increase in the percentage of d covered from the baseline period through 24 wk</td><td>Change in knowledge of hydroxyurea in the 5-item HU knowledge scale:<list list-type="simple" id="ulist0015"><list-item id="u0020"><label>•</label><p id="p0580">mean score changed from 4.6 to 4.7, <italic>P</italic> = .095).</p></list-item><list-item id="u0025"><label>•</label><p id="p0585">baseline scores ≥4: 62/69 (89.9%) providers</p></list-item><list-item id="u0030"><label>•</label><p id="p0590">baseline scores &lt;4, 7/69 (10.1%) providers. Their mean scores improved from 2.1 to 3.4 (<italic>P</italic> = .022).</p></list-item><list-item id="u0035"><p id="p0595">Change in self-efficacy of hydroxyurea administration in the 12-item scale:</p></list-item><list-item id="u0040"><label>•</label><p id="p0600">mean score changed from 9.6 to 9.5, <italic>P</italic> = .96;</p></list-item><list-item id="u0045"><label>•</label><p id="p0605">baseline scores ≥6: 46/73 (91.8%) providers;</p></list-item><list-item id="u0050"><label>•</label><p id="p0610">baseline scores &lt;6: 6/73 (8.2%) providers. Their mean scores improved from 3.6 to 8.6 (<italic>P</italic> = .042).</p></list-item></list></td></tr><tr><td>Adoption</td><td>Percentage of clinics in each site agreeing to support InCharge Health: all 15 participating clinics received training in how to download and use the InCharge Health app; all approached and enrolled potential participants.</td><td>Percentage of eligible providers approached: all providers in all participating clinics were approached to participate in the study (100%).<break/>The proportion of enrolled providers in the study among all eligible providers at each site: 89/104 (85.6%)</td></tr><tr><td>Implementation</td><td>Percentage of all enrolled patients who used the InCharge Health app at least once during the study period: 240/293 (81.9%), median use 26 d (IQR, 7-72 d).<break/>Percentage of all enrolled patients who used the InCharge Health app during the study period &gt;1 d: 224/293 (76.5%).<break/>Percentage of all evaluable patients who used InCharge Health at least one d during the study period: 199/235 (84.7%), median use 17 d (range, 1 to 156 of 168 d).<break/>Percentage of all evaluable patients who used InCharge Health &gt;1 d during the study period: 185/235 (78.7%)</td><td>Percentage of enrolled providers who used the HU Toolbox app during the study period at least once: 58/89 (65.2%).<break/>At least a single use of the app by provider type:<list list-type="simple" id="ulist0020"><list-item id="u0055"><label>•</label><p id="p0615">physicians: 34 of 49 (69.4%);</p></list-item><list-item id="u0060"><label>•</label><p id="p0620">PAs/NPs: 23 of 36 (63.9%).</p></list-item></list>10 (11.2%) of all providers used the app at least 6 d over 168 d (i.e., at least once per mo)</td></tr><tr><td>Maintenance</td><td>Percentage of enrolled patients who used the InCharge Health app in the post-study period &gt;1 d: 133/293 (56.6%), median use 17 of 84 d (range, 1-82 d)<break/>Percentage of evaluable patients who used the InCharge Health app in the post-study period &gt;1 d: 118/235 (50.2%), median use 19 of 84 d (range, 1-82 d)<break/>Mean change in hydroxyurea adherence among those receiving the intervention and evaluable: 11.8% (<italic>P</italic> &lt; .0001) increase in the percentage of d covered from the baseline period through the post-study period</td><td>Percentage of enrolled providers who used the HU Toolbox app in the post-study period at least once: 10/89 (11.2%)</td></tr></tbody></table><table-wrap-foot><fn><p>The study period includes the period between baseline through week 24. The poststudy period includes weeks 24 through 36.</p></fn></table-wrap-foot><table-wrap-foot><fn id="tbl2fnlowast"><label>∗</label><p id="ntpara0025">Evaluable patients had baseline and week 24 PDC data and were included in the primary outcome analysis for effectiveness, n = 235.</p></fn></table-wrap-foot></table-wrap></p>
                <p id="p0095">Of the 89 providers, 49 (57.7%) were physicians (most hematologists or with substantial SCD experience), and the remaining were nurse practitioners (n = 27), physician assistants (n = 9), primarily working in hematology clinics, or preferred not to report their position (n = 4; <xref rid="tbl1" ref-type="table">Table 1</xref>). Most providers were female non-Hispanic White, or Asian, aged between 30 and 60 years. Among the 89 enrolled providers, 6 relocated to other institutions and were removed, and 11 had incomplete baseline activities (ie, did not download the HU Toolbox or complete the study surveys) or withdrew participation. Therefore, provider retention was 81%.</p>
              </sec>
              <sec id="sec3.2">
                <title>mHealth app RE-AIM outcomes</title>
                <p id="p0100">The study acceptance rate was 85%, and approximately half of all eligible patients were enrolled (<xref rid="tbl2" ref-type="table">Table 2</xref>). Approximately 85% of patients used the app &gt;1 day during the study period (<xref rid="tbl2" ref-type="table">Table 2</xref>). Overall, the patients reported that the app was easy to navigate and understand. Among evaluable participants, use-days of the InCharge Health app ranged from 1 to 156 of 168 days (0.6%-92.9%; median, 17.0%; interquartile range, 4.8%-45.8%) and was greater among patients aged between 25 and 45 vs those between 15 and 24 years (44.02±44.7 vs 27.63 study days, <italic>P</italic> = .0032). All 7 sites actively participated in the study, and 85.6% of providers agreed to participate. Implementation of HU Toolbox was low; 58 of 89 providers (65.2%) downloaded and used the HU Toolbox app at least once, but only 10 (11.2%) used the app at least 6 days over 168 days (maximum, 18 days). Most use occurred in the first 6 months, with 117 (54.4%) of 215 days on which the HU Toolbox app occurred in the first month, and only 4 (1.9%) occurred in month 6. Patients continued app use at a slower pace (50.2% &gt;1 day) after the study (<xref rid="appsec1" ref-type="sec">supplemental Table 3</xref>). Providers had low poststudy use (11.2% &gt;1 day). More detailed results of the RE-AIM evaluation are presented in <xref rid="tbl2" ref-type="table">Table 2</xref>.</p>
              </sec>
              <sec id="sec3.3">
                <title>Change in hydroxyurea adherence</title>
                <p id="p0105">Mean PDC increased from 39.7% (±28.0% standard deviation [SD]) at baseline to 56.0% (±30.1% SD) during the 24-week follow-up interval (<italic>P</italic> &lt; .0001), a relative increase of 29.1% and an absolute increase of 16.3% (median absolute increase, 17.8%). The null hypothesis was rejected, and the study end point was met.</p>
                <p id="p0110">PDC over the 24-week follow-up period could not be calculated for 14 participants because of missing 24-week prescription data. Adding these participants to the 235 participants in the analytical cohort, with zeros replacing the missing values, reduced the mean absolute change in PDC to 14.8%, which remained significantly greater than zero (<italic>P</italic> &lt; .0001).</p>
                <p id="p0115">Adherence ≥80% is optimal to increase the likelihood of the best clinical benefits from medication.<xref rid="bib7" ref-type="bibr"><sup>7</sup></xref><sup>,</sup><xref rid="bib12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="bib13" ref-type="bibr"><sup>13</sup></xref> PDC increased from &lt;80% at baseline to ≥80% at follow-up for 50 of 235 subjects and decreased from ≥80% at baseline to &lt;80% at follow-up for 12 subjects, resulting in a net change from 20 (8.5%) subjects with PDC &gt;80% at baseline to 56 (23.8%) with PDC ≥80% at follow-up (<italic>P</italic> &lt; .0001). The highest mean increases occurred among the 215 participants with baseline PDC &lt;80%, from 34.9% (±23.8% SD) to 54.6% (±29.9% SD), an absolute increase of 19.8%; <italic>P</italic> = .0001. Individuals whose PDC increased from &lt;80% at baseline to ≥80% at follow-up trended toward using the app more often than all others (mean, 48 ± 48.8 vs 34.8 ± 39.5 days; <italic>P</italic> = .08). Baseline PDC did not predict app use (<italic>r</italic> = 0.0066; <italic>P</italic> = .91).</p>
                <p id="p0120">The 36-week PDC was available for 232 of 235 subjects. PDC remained higher at 51.4% (29.4% SD) in the 12 weeks after study completion relative to that at baseline (mean difference, 11.65%; <italic>P</italic> &lt; .001).</p>
              </sec>
              <sec id="sec3.4">
                <title>Predictors of adherence change</title>
                <p id="p0125">Frequency of app use, health insurance plan type, frequency of pain in the past 12 months, and severe pain frequency and interference in the past 6 months, with the 3 pain measures all reported at enrollment, were all associated with greater change in PDC (<xref rid="appsec1" ref-type="sec">supplemental Table 1</xref>). Although as little as 13 days of app use was associated with significant PDC increases, patients who used the app for &gt;50% of the duration of the study (≥85 days) saw the greatest mean increase in PDC (26.9%) (<xref rid="tbl3" ref-type="table">Table 3</xref>).<table-wrap position="float" id="tbl3"><label>Table 3.</label><caption><p><bold>Relationship between frequency of InCharge Health app use and PDC change</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th>% d of app use over 168 study d (# days)</th><th align="center">N</th><th align="center">Adjusted mean change in PDC (95% CLs)</th></tr></thead><tbody><tr><td>≥50.1% (≥85 d)</td><td align="char">45</td><td align="char">26.9 (18.8-35.1)</td></tr><tr><td>&gt;21.5%, &lt;50.1% (37-84 d)</td><td align="char">44</td><td align="char">19.3 (11.1-27.6)</td></tr><tr><td>&gt;7.2%, &lt;21.5% (13-36 d)</td><td align="char">45</td><td align="char">13.3 (5.1-21.5)</td></tr><tr><td>&gt;0.6%, &lt;7.2% (2-12 d)</td><td align="char">51</td><td align="char">8.1 (0.5-15.8)</td></tr><tr><td>&lt;0.6% (0-1 d)</td><td align="char">50</td><td align="char">15.4 (7.6-23.1)</td></tr></tbody></table><table-wrap-foot><fn><p>CL, confidence limits; PDC, percentage of days covered.</p></fn></table-wrap-foot></table-wrap></p>
                <p id="p0130">Patients with private insurance had a larger adjusted mean increase in PDC, followed by those with government insurance (<xref rid="appsec1" ref-type="sec">supplemental Table 4</xref>). Adjusted mean change in PDC varied inversely with severe pain frequency in the last 6 months, the frequency of pain interference in the last 6 months, and the frequency of pain episodes in the previous 12 months (<xref rid="tbl4" ref-type="table">Table 4</xref>). Larger adjusted increase in PDC was seen in patients aged between 35 and 39 and between 40 and 45 years compared with that in younger patients (<xref rid="appsec1" ref-type="sec">supplemental Table 4</xref>).<table-wrap position="float" id="tbl4"><label>Table 4.</label><caption><p><bold>Relationship between pain patterns and PDC change</bold></p></caption><table frame="hsides" rules="groups"><thead><tr><th>Severe pain in the last 6 mo</th><th align="center">N</th><th align="center">Mean change in PDC (95% CLs)</th><th align="center">Pain interference on activities in the last 6 mo</th><th align="center">N</th><th align="center">Mean change in PDC (95% CLs)</th><th align="center">Frequency of pain episodes in the last 12 mo</th><th align="center">N</th><th align="center">Mean change in PDC (95% CLs)</th></tr></thead><tbody><tr><td>Never</td><td align="char">18</td><td align="char"><bold>35.9 (22.9-49.0)</bold></td><td align="center"><bold>Never</bold></td><td align="char">30</td><td align="char"><bold>36.2 (26.4-46.0)</bold></td><td align="center"><bold>None</bold></td><td align="char">32</td><td align="char"><bold>29.0 (19.3-38.7)</bold></td></tr><tr><td>Rarely</td><td align="char">61</td><td align="char"><bold>15.7 (8.6-22.7)</bold></td><td align="center"><bold>Rarely</bold></td><td align="char">63</td><td align="char"><bold>14.1 (7.4-20.9)</bold></td><td align="center"><bold>1</bold></td><td align="char">29</td><td align="char"><bold>20.5 (10.3-30.7)</bold></td></tr><tr><td>Sometimes</td><td align="char">89</td><td align="char"><bold>15.2 (9.4-21.0)</bold></td><td align="center"><bold>Sometimes</bold></td><td align="char">81</td><td align="char"><bold>16.0 (10.0-21.9)</bold></td><td align="center"><bold>2</bold></td><td align="char">38</td><td align="char"><bold>14.2 (5.2-23.1)</bold></td></tr><tr><td>Often</td><td align="char">54</td><td align="char"><bold>13.4 (5.9-20.9)</bold></td><td align="center"><bold>Often</bold></td><td align="char">48</td><td align="char"><bold>10.6 (2.9-18.4)</bold></td><td align="center"><bold>3</bold></td><td align="char">30</td><td align="char"><bold>17.8 (7.7-27.9)</bold></td></tr><tr><td>Always</td><td align="char">11</td><td align="char">6.7 (−9.9 to 23.2)</td><td align="center"><bold>Always</bold></td><td align="char">11</td><td align="char">−2.6 (−18.7 to 13.6)</td><td align="center"><bold>4 or more</bold></td><td align="char">104</td><td align="char"><bold>11.7 (6.3-17.0)</bold></td></tr></tbody></table><table-wrap-foot><fn><p>CL, confidence limits. Bold indicates significance at the <italic>P</italic> &lt; 0.05 level.</p></fn></table-wrap-foot></table-wrap></p>
                <p id="p0135">The number of provider participants per clinic ranged from 1 to 36 (median = 14 providers). Mean change in PDC per clinic, controlling for mean baseline PDC per clinic, was not associated with mean HU Toolbox use (<italic>P</italic> = .98).</p>
                <p id="p0140">In multivariable analysis, controlling for baseline PDC and site, greater app use, older age, having private insurance, and experiencing less pain interference in the previous 6 months were significantly associated with higher PDC increases after backward elimination. When clinic replaced site in the multivariable model, results were similar, except that pain frequency in the past 12 months replaced pain interference (<xref rid="appsec1" ref-type="sec">supplemental Table 5</xref>).</p>
              </sec>
              <sec id="sec3.5">
                <title>Acute care use, laboratory markers, and PRO measures</title>
                <p id="p0145">The number of ED visits for pain declined with increasing PDC in both the baseline and follow-up intervals (baseline, <italic>P</italic> = .0013; follow-up, <italic>P</italic> &lt; .0001) as did the number of admissions for pain (baseline, <italic>P</italic> = .0318; follow-up, <italic>P</italic> = .0003). However, changes in PDC among intervals were not associated with changes in either ED visits or admissions for pain (ED visits, <italic>r</italic> = –0.03; <italic>P</italic> = .62; admissions, <italic>r</italic> = 0.0648; <italic>P</italic> = .32). Although the rate of ED visits increased (1.16 to 1.51 visits per patient), it reflected a small number of subjects with large changes in ED visits rather than a general trend. Excluding the extreme values, mean change was only 0.036 visits per patient. Individuals who had at least 1 admission during the baseline period experienced a 25% reduction in hospitalizations for pain, with the rate dropping from 1.97 to 1.48 events per 24 weeks per patient (<italic>P</italic> = .0045; <xref rid="appsec1" ref-type="sec">supplemental Table 6</xref>). Moreover, these individuals maintained lower hospitalization rates after the study’s completion, decreasing from 1.97 to 1.25 events per 24 weeks per patient (35% reduction from baseline; <italic>P</italic> = .015; <xref rid="appsec1" ref-type="sec">supplemental Table 6</xref>). Patients without admissions in the baseline period did not exhibit any noticeable difference in hospitalization rates.</p>
                <p id="p0150">After 24 weeks of intervention, mean HbF increased, whereas ANC and count of reticulocytes declined, compared with values at baseline. No other laboratory changes were found (<xref rid="appsec1" ref-type="sec">supplemental Table 6</xref>). PDC change was associated with a change in HbF (<italic>r</italic> = 0.21; <italic>P</italic> = .02). During the poststudy period, reticulocytes remained lower than the baseline. There were no other significant changes in laboratories (<xref rid="appsec1" ref-type="sec">supplemental Table 6</xref>).</p>
                <p id="p0155">Patient-Reported Outcomes Measurement Information System and Adult Sickle Cell Quality of Life Measurement Information System PROs were analyzed for pain frequency, quality, severity, and interference data at baseline and at week 24. The mean frequency of self-reported pain in the past 12 months declined from 3.54 events per patient at baseline to 3.35 events per patients at follow-up (<italic>P</italic> = .0412). No other changes in PROs were detected (<xref rid="appsec1" ref-type="sec">supplemental Table 6</xref>).</p>
              </sec>
              <sec id="sec3.6">
                <title>Providers knowledge and self-efficacy</title>
                <p id="p0160">Throughout the study, providers demonstrated consistently high levels of knowledge and self-efficacy in prescribing hydroxyurea, with mean scores of 4.6 of 5 (baseline) and 4.7 of 5 (follow-up) for knowledge, and 9.6 of 12 (baseline) and 9.5 of 12 (follow-up) for self-efficacy. However, providers who initially exhibited lower levels of hydroxyurea knowledge and self-efficacy experienced significant improvement during the study (<xref rid="tbl2" ref-type="table">Table 2</xref>). No significant differences in scores were appreciated between physicians and advanced practice providers (ie, nurse practitioners and physician assistants).</p>
              </sec>
            </sec>
            <sec id="sec4">
              <title>Discussion</title>
              <p id="p0165">To our knowledge, in the first study of its kind, we tested the effectiveness and implementation of a multilevel intervention to act on the behavioral determinants of low hydroxyurea adherence in patients with SCD and their providers, leveraging mHealth to deliver both interventions. In a multicenter proof-of-concept nonrandomized prospective clinical trial, we found a significant absolute mean increase of 16.3% in adherence, which sustained and promoted a 25% reduction in admissions for pain. This effect size is equivalent to using hydroxyurea slightly over 1 day per week. Our findings mirrored those of previous studies on mHealth adherence in chronic conditions, such as cardiovascular disease, asthma, and hypertension, which have demonstrated similar effect sizes ranging from 5% to 32%.<xref rid="bib38" ref-type="bibr">38</xref>, <xref rid="bib39" ref-type="bibr">39</xref>, <xref rid="bib40" ref-type="bibr">40</xref>, <xref rid="bib41" ref-type="bibr">41</xref>, <xref rid="bib42" ref-type="bibr">42</xref> Our data indicate that the use of mHealth by patients (but not providers) was associated with better hydroxyurea adherence and potential clinical benefit.</p>
              <p id="p0170">We did not observe MCV rise, but other laboratory markers of hydroxyurea effect (HbF, ANC, and reticulocytes) reflected improved adherence. The slight increase in HbF (1.9%) may not be clinically meaningful and could reflect stress erythropoiesis owing to hypoxia adaptation.<xref rid="bib43" ref-type="bibr"><sup>43</sup></xref> The lack of overall reduction in acute care use and MCV rise likely stems from the very low overall baseline adherence level (&lt;40%) and because only a quarter of patients crossed the 80% threshold for optimal adherence. Traditional efficacy clinical trials invariably select the most adherent patients for participation, which does not reflect real-world experiences. Our study represents a signal of effect that could be refined for future and more definitive implementation studies that will raise adherence &gt;80%.</p>
              <p id="p0175">The COVID-19 pandemic had possible negative effects on the study. Clinic shutdowns, suspension of non–COVID-19 research activities, and staff resignation, all reduced hydroxyurea prescribing practices, curtailed app use, and created barriers to enrollment.<xref rid="bib44" ref-type="bibr"><sup>44</sup></xref> The magnitude of the findings of this study may have been diminished owing to this global emergency. Because this study occurred during the COVID-19 pandemic, when care use fluctuated, these findings must be replicated.</p>
              <p id="p0180">Compared with older adults, adolescents and young adults used the app less and had less of an increase in medication adherence. This finding challenges the assumption that adolescents and young adults most benefit from modern technology interventions. Despite widespread acceptance of mobile devices and phone applications, younger patients may require additional support to sustain good self-management practices, given their developmental stage and maturity level. This is particularly relevant, because hydroxyurea adherence declines during adult care transition,<xref rid="bib10" ref-type="bibr"><sup>10</sup></xref> thus threatening its long-term benefits, including organ protection. To achieve a higher number of patients with optimal medication adherence (ie, PDC ≥80%) and potentially engage younger patients, additional evidence-based interventions tailored to the determinants of low adherence should be tested concurrently with mHealth to boost and sustain adherence. For example, motivational interviewing is an evidence–based behavioral intervention successfully used to improve medication adherence in young<xref rid="bib45" ref-type="bibr"><sup>45</sup></xref> and older<xref rid="bib46" ref-type="bibr"><sup>46</sup></xref> adults with chronic diseases. It could be combined with mHealth interventions to improve hydroxyurea adherence and app engagement.</p>
              <p id="p0185">Reduced adherence to medication was observed in cases where baseline pain severity, frequency, and interference were higher. Sometimes, it is uncertain whether pain contributes to low adherence or vice versa. Thus, addressing the burden of pain is crucial to improving medication adherence. Furthermore, the type of health coverage seemed to predict intervention response, with private insurance associated with higher adherence. Health inequities are a product of social opportunities linked to economic barriers. As such, individuals with public insurance may also experience poverty, lower levels of digital literacy, and less social support. Any intervention focused on improving adherence must effectively address socio determinants of health to achieve the best results.</p>
              <p id="p0190">InCharge Health app implementation was high (∼85% downloaded and used the app at least once). However, app engagement was relatively low (∼17% of patients used the app &gt;50% of the days in the study) and declined after the study. Other mHealth studies in SCD showed similar difficulty engaging with patients and waned use over time.<xref rid="bib47" ref-type="bibr"><sup>47</sup></xref><sup>,</sup><xref rid="bib48" ref-type="bibr"><sup>48</sup></xref> Engagement with digital interventions involves investing affective, cognitive, and physical energies. Thus, low affective investment in the digital tool and low momentary motivation are common reasons for app disengagement.<xref rid="bib49" ref-type="bibr"><sup>49</sup></xref> We are still in the infancy of understanding and measuring what is a meaningful amount and pattern of app engagement to promote effective and sustained behavior changes.<xref rid="bib50" ref-type="bibr"><sup>50</sup></xref> Thus, understanding the factors predicting app engagement, user’s experience, how often and how apps are used is critical, and the next steps in our research.</p>
              <p id="p0195">Although adoption of HU Toolbox among providers was relatively high (65% agreed to use it), only 11% meaningfully used the app during the study. Our study included mainly academic sites and clinics, with access to providers who consider themselves SCD specialists.<xref rid="bib51" ref-type="bibr"><sup>51</sup></xref> It is possible that participating providers did not see the need to use the app, because most were from academic sites or practiced at SCD specialty clinics. Because we firmly believe that improvement in hydroxyurea prescribing practices is needed in the United States, modifications to the provider app are planned to bolster its usability for future testing among non-SCD experts. We will, however, omit this intervention in future studies of experienced SCD clinicians.</p>
              <p id="p0200">Limitations of the study included a lack of a control group, short poststudy follow-up, and missing follow-up prescription data in 9.6% of patients. Although to a lesser extent than high app users, low app users also saw an increase in PDC, likely a limitation of the study design. As with many nonrandomized intervention studies, we cannot eliminate all threats to internal validity, including potential compensatory behaviors that may affect the extent and timing of the intervention’s effects.<xref rid="bib52" ref-type="bibr"><sup>52</sup></xref> However, we point to the following to highlight the plausibility that the app was responsible for the rise in PDC: (1) baseline PDC did not predict app use, (2) research staff and patient contact was brief and constrained to only 3 study visits, (3) higher than observed PDC change would have been expected should the patients who could not be evaluated had been included, given their lower baseline PDC and the negative correlation between baseline PDC and change in PDC, and (4) persistence of treatment response beyond the intervention period is not predicted by compensatory behaviors. Despite the limitations of the study design, we observed some benefits of mHealth intervention.</p>
              <p id="p0205">Although patients present themselves as taking the medication at study entry, upon reviewing pharmacy records, they often do not. This scenario reflects the challenges of conducting effectiveness studies, that is, outside the artificial setting of clinical trials. Given our implementation-effectiveness study design, we intentionally did not use a direct measure of adherence but inferred it from medication refills. This is both a strength for reflecting real-world practices and a limitation, because there was no way of knowing if drug possession equated to ingestion. Although cognitive function difficulties affect hydroxyurea adherence,<xref rid="bib53" ref-type="bibr"><sup>53</sup></xref> our study did not measure if the app could have mitigated the effects of cognitive dysfunction on medication adherence. Future studies should include cognitive assessments and how they may change during the mHealth intervention. Furthermore, patients with high baseline adherence participated, which may have diminished effectiveness, because a PDC of 90% can only increase it by an additional 10%. Restricting the intervention to individuals with low adherence is planned in future studies.</p>
              <p id="p0210">In conclusion, in a multicenter prospective intervention study, an mHealth intervention tailored to the determinants of low hydroxyurea adherence among patients with SCD promoted a 29% relative increase in adherence. Concomitant provider use of mHealth to support hydroxyurea prescribing did not help in increasing adherence in this study of primary academic sites. The use of the patient mHealth intervention to increase hydroxyurea adherence promoted improvement of some hematologic markers of hydroxyurea effect, reduced pain admissions, and self-reported frequency of pain. Although not definitive, the results from this large mHealth study are encouraging and support a randomized clinical trial with a longer poststudy observation period to increase hydroxyurea adherence further and improve health outcomes.</p>
            </sec>
            <sec id="sec5">
              <title>Appendix</title>
              <p id="p0215">The Sickle Cell Disease Implementation Consortium (SCDIC) participating site members are:</p>
              <p id="p0220">ST. JUDE CHILDREN’S RESEARCH HOSPITAL</p>
              <p id="p0225">Jane S. Hankins, Jason Hodges, Yvonne Carroll, Lisa Klesges, Hamda Khan, Matthew Smeltzer, Chinonyelum Nwosu, James Gurney, Jerlym Porter, Nicole Alberts, Reginald French, Sherif Badawy, Michael DeBaun, Guolian Kang, Jeremie Estepp, Winfred Wang, Curtis Owens, Margaret Debon, Ray Osarogiagbon, Marquita Nelson</p>
              <p id="p0230">UNIVERSITY OF CALIFORNIA IN SAN FRANCISCO</p>
              <p id="p0235">Marsha Treadwell, Elliott Vichinsky, Ted Wun, Michael Potter, Danielle Hessler, Ward Hagar, Anne Marsh, Lynne Neumayr</p>
              <p id="p0240">MEDICAL UNIVERSITY OF SOUTH CAROLINA</p>
              <p id="p0245">Cathy Melvin, Julie Kanter, Shannon Phillips, Robert Adams, Martina Mueller, Tina Abrams, Nathalia Davia</p>
              <p id="p0250">DUKE UNIVERSITY</p>
              <p id="p0255">Nirmish Shah, Paula Tanabe, Hayden Bosworth, George Jackson, Fred Johnson, Rachel Richesson, Janet Prvu-Bettger</p>
              <p id="p0260">WASHINGTON UNIVERSITY</p>
              <p id="p0265">Allison King, Ana Baumann, Cecilia Calhoun</p>
              <p id="p0270">AUGUSTA UNIVERSITY</p>
              <p id="p0275">Abdullah Kutlar, Robert Gibson, Angie Snyder, Maria Fernandez, Richard Lottenberg</p>
              <p id="p0280">MT SINAI</p>
              <p id="p0285">Lynne D. Richardson, Jeffrey Glassberg, Jena Simon, Nicholas G. Genes, George T. Loo, Jason S. Shapiro, Kimberly Souffront, Cindy Clesca, Elizabeth Linton, Gery Ryan</p>
              <p id="p0300">RTI INTERNATIONAL</p>
              <p id="p0305">Barbara L. Kroner, Tabitha Hendershot, Lisa DiMartino, Sara Jacobs, Whitney Battestilli, Donald Brambilla, Lisa Cox, Liliana Preiss, Norma Pugh, Sophie Li, Annie VonLehmden</p>
              <p id="p0310">NHLBI</p>
              <p id="p0315">Sharon M. Smith, William P. Tonkins, Marlene Peters-Lawrence, Cheryl Boyce, Whitney Barfield</p>
              <p id="p0340">LURIE CHILDREN’S</p>
              <p id="p0345">Alexis Thompson</p>
              <p id="p0350">UNIVERSITY OF ILLINOIS AT CHICAGO</p>
              <p id="p0355">Principal Investigators</p>
              <p id="p0360">Victor Gordeuk, a</p>
              <p id="p0365">Melissa Gutierrez, i, j</p>
              <p id="p0370">Jana Hirschtick, i, j, Lewis Hsu, b, Jerry Krishnan, c</p>
              <p id="p0375">Nadew Sebro, j</p>
              <p id="p0380">Larissa Verda, j</p>
              <p id="p0385">Abe Wandersman, k</p>
              <p id="p0390">Co-Investigators</p>
              <p id="p0395">Michael Berbaum, f</p>
              <p id="p0400">Kishore Bobba, j</p>
              <p id="p0405">Joe Colla, g</p>
              <p id="p0410">Kim Erwin, d</p>
              <p id="p0415">Andrea Lamont, k</p>
              <p id="p0420">Molly Martin, b</p>
              <p id="p0425">Sarah Norell, d</p>
              <p id="p0430">Ananta Pandit, j</p>
              <p id="p0435">Kay Saving, h</p>
              <p id="p0440">Robin Shannon, e</p>
              <p id="p0445">Robert Winn, c</p>
              <p id="p0450">Leslie Zun, j</p>
              <p id="p0455">Research Staff</p>
              <p id="p0460">Taif Hassan, a</p>
              <p id="p0465">Patricia Lasley, j</p>
              <p id="p0470">Kristin Monnard, i, j</p>
              <p id="p0475">Judith Nocek, a</p>
              <p id="p0480">Pamela Roesch, i, j</p>
              <p id="p0485">Affiliation</p>
              <p id="p0490">a. University of Illinois at Chicago, Division of Hematology and Oncology</p>
              <p id="p0495">b. University of Illinois at Chicago, Department of Pediatrics</p>
              <p id="p0500">c. University of Illinois at Chicago, Division of Pulmonary, Critical Care, Sleep and Allergy, Associate Vice Chancellor for Population Health Sciences</p>
              <p id="p0505">d. Program for Healthcare Delivery Design, Population Health Sciences Program, Office of the Vice Chancellor for Health Affairs</p>
              <p id="p0510">e. University of Illinois at Chicago, College of Nursing</p>
              <p id="p0515">f. University of Illinois at Chicago, Department of Epidemiology and Biostatistics</p>
              <p id="p0520">g. University of Illinois Health, Department of Emergency Medicine</p>
              <p id="p0525">h. University of Illinois College of Medicine, Peoria</p>
              <p id="p0530">i. Sinai Urban Health Institute</p>
              <p id="p0535">j. Sinai Health System</p>
              <p id="p0540">k. University of South Carolina</p>
            </sec>
            <sec sec-type="COI-statement">
              <p id="p0545">Conflict-of-interest disclosure: J.S.H. receives consultancy fees from Forma Therapeutics and Global Blood Therapeutics (GBT). N.S. receives consultancy fees from GBT, Forma, Agios, Bausch, and bluebird bio, and speaks for GBT, Emmaus Pharmaceuticals, and Alexion. L.L.H. received consultancy fees from Hilton Publishing HPC, Forma Therapeutic, Emmaus, Novartis, and Aruvant, and research funding from <funding-source id="gs5">Asklepion</funding-source>, <funding-source id="gs6"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004319</institution-id><institution>Pfizer</institution></institution-wrap></funding-source>, <funding-source id="gs7">CRISPR</funding-source>/<funding-source id="gs8">Vertex</funding-source>, and <funding-source id="gs9"><institution-wrap><institution-id institution-id-type="doi">10.13039/100004326</institution-id><institution>Bayer</institution></institution-wrap></funding-source>.</p>
              <p id="p0550">The current affiliation for L.D. is The University of Texas Southwestern Medical Center, Dallas, TX.</p>
              <p id="p0555">A complete list of the members of the Sickle Cell Disease Implementation Consortium appears in “Appendix.”</p>
            </sec>
          </body>
          <back>
            <ref-list id="cebib0010">
              <title>References</title>
              <ref id="bib1">
                <label>1</label>
                <element-citation publication-type="journal" id="sref1">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rai</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Desai</surname>
                      <given-names>PC</given-names>
                    </name>
                    <name>
                      <surname>Ataga</surname>
                      <given-names>KI</given-names>
                    </name>
                  </person-group>
                  <article-title>The evolving landscape of drug therapies for sickle cell disease</article-title>
                  <source>Hematol Oncol Clin North Am</source>
                  <volume>36</volume>
                  <issue>6</issue>
                  <year>2022</year>
                  <fpage>1285</fpage>
                  <lpage>1312</lpage>
                  <pub-id pub-id-type="pmid">36400544</pub-id>
                </element-citation>
              </ref>
              <ref id="bib2">
                <label>2</label>
                <element-citation publication-type="journal" id="sref2">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Rankine-Mullings</surname>
                      <given-names>AE</given-names>
                    </name>
                    <name>
                      <surname>Nevitt</surname>
                      <given-names>SJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Hydroxyurea (hydroxycarbamide) for sickle cell disease</article-title>
                  <source>Cochrane Database Syst Rev</source>
                  <volume>9</volume>
                  <issue>9</issue>
                  <year>2022</year>
                  <fpage>CD002202</fpage>
                  <pub-id pub-id-type="pmid">36047926</pub-id>
                </element-citation>
              </ref>
              <ref id="bib3">
                <label>3</label>
                <element-citation publication-type="journal" id="sref3">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Heitzer</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Longoria</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Okhomina</surname>
                      <given-names>V</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Hydroxyurea treatment and neurocognitive functioning in sickle cell disease from school age to young adulthood</article-title>
                  <source>Br J Haematol</source>
                  <volume>195</volume>
                  <issue>2</issue>
                  <year>2021</year>
                  <fpage>256</fpage>
                  <lpage>266</lpage>
                  <pub-id pub-id-type="pmid">34272726</pub-id>
                </element-citation>
              </ref>
              <ref id="bib4">
                <label>4</label>
                <element-citation publication-type="journal" id="sref4">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Yang</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Elmuti</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Badawy</surname>
                      <given-names>SM</given-names>
                    </name>
                  </person-group>
                  <article-title>Health-related quality of life and adherence to hydroxyurea and other disease-modifying therapies among individuals with sickle cell disease: a systematic review</article-title>
                  <source>Biomed Res Int</source>
                  <volume>2022</volume>
                  <year>2022</year>
                  <object-id pub-id-type="publisher-id">2122056</object-id>
                </element-citation>
              </ref>
              <ref id="bib5">
                <label>5</label>
                <element-citation publication-type="journal" id="sref5">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Fitzhugh</surname>
                      <given-names>CD</given-names>
                    </name>
                    <name>
                      <surname>Hsieh</surname>
                      <given-names>MM</given-names>
                    </name>
                    <name>
                      <surname>Allen</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Hydroxyurea-increased fetal hemoglobin is associated with less organ damage and longer survival in adults with sickle cell anemia</article-title>
                  <source>PLoS One</source>
                  <volume>10</volume>
                  <issue>11</issue>
                  <year>2015</year>
                  <object-id pub-id-type="publisher-id">e0141706</object-id>
                </element-citation>
              </ref>
              <ref id="bib6">
                <label>6</label>
                <element-citation publication-type="journal" id="sref6">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lobo</surname>
                      <given-names>CL</given-names>
                    </name>
                    <name>
                      <surname>Pinto</surname>
                      <given-names>JF</given-names>
                    </name>
                    <name>
                      <surname>Nascimento</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Moura</surname>
                      <given-names>PG</given-names>
                    </name>
                    <name>
                      <surname>Cardoso</surname>
                      <given-names>GP</given-names>
                    </name>
                    <name>
                      <surname>Hankins</surname>
                      <given-names>JS</given-names>
                    </name>
                  </person-group>
                  <article-title>The effect of hydroxcarbamide therapy on survival of children with sickle cell disease</article-title>
                  <source>Br J Haematol</source>
                  <volume>161</volume>
                  <issue>6</issue>
                  <year>2013</year>
                  <fpage>852</fpage>
                  <lpage>860</lpage>
                  <pub-id pub-id-type="pmid">23590693</pub-id>
                </element-citation>
              </ref>
              <ref id="bib7">
                <label>7</label>
                <element-citation publication-type="journal" id="sref7">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kang</surname>
                      <given-names>HA</given-names>
                    </name>
                    <name>
                      <surname>Barner</surname>
                      <given-names>JC</given-names>
                    </name>
                    <name>
                      <surname>Lawson</surname>
                      <given-names>KA</given-names>
                    </name>
                    <name>
                      <surname>Rascati</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Mignacca</surname>
                      <given-names>RC</given-names>
                    </name>
                  </person-group>
                  <article-title>Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease</article-title>
                  <source>Am J Hematol</source>
                  <volume>98</volume>
                  <issue>1</issue>
                  <year>2023</year>
                  <fpage>90</fpage>
                  <lpage>101</lpage>
                  <pub-id pub-id-type="pmid">36251408</pub-id>
                </element-citation>
              </ref>
              <ref id="bib8">
                <label>8</label>
                <element-citation publication-type="journal" id="sref8">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lobo</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Moura</surname>
                      <given-names>P</given-names>
                    </name>
                    <name>
                      <surname>Fidlarczyk</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Cost analysis of acute care resource utilization among individuals with sickle cell disease in a middle-income country</article-title>
                  <source>BMC Health Serv Res</source>
                  <volume>22</volume>
                  <issue>1</issue>
                  <year>2022</year>
                  <fpage>42</fpage>
                  <pub-id pub-id-type="pmid">34998394</pub-id>
                </element-citation>
              </ref>
              <ref id="bib9">
                <label>9</label>
                <element-citation publication-type="journal" id="sref9">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Reeves</surname>
                      <given-names>SL</given-names>
                    </name>
                    <name>
                      <surname>Jary</surname>
                      <given-names>HK</given-names>
                    </name>
                    <name>
                      <surname>Gondhi</surname>
                      <given-names>JP</given-names>
                    </name>
                    <name>
                      <surname>Raphael</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Lisabeth</surname>
                      <given-names>LD</given-names>
                    </name>
                    <name>
                      <surname>Dombkowski</surname>
                      <given-names>KJ</given-names>
                    </name>
                  </person-group>
                  <article-title>Hydroxyurea use among children with sickle cell anemia</article-title>
                  <source>Pediatr Blood Cancer</source>
                  <volume>66</volume>
                  <issue>6</issue>
                  <year>2019</year>
                  <object-id pub-id-type="publisher-id">e27721</object-id>
                </element-citation>
              </ref>
              <ref id="bib10">
                <label>10</label>
                <element-citation publication-type="journal" id="sref10">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mathias</surname>
                      <given-names>JG</given-names>
                    </name>
                    <name>
                      <surname>Nolan</surname>
                      <given-names>VG</given-names>
                    </name>
                    <name>
                      <surname>Klesges</surname>
                      <given-names>LM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Hydroxyurea use after transitions of care among young adults with sickle cell disease and Tennessee Medicaid Insurance</article-title>
                  <source>JAMA Netw Open</source>
                  <volume>4</volume>
                  <issue>10</issue>
                  <year>2021</year>
                  <object-id pub-id-type="publisher-id">e2128971</object-id>
                </element-citation>
              </ref>
              <ref id="bib11">
                <label>11</label>
                <element-citation publication-type="journal" id="sref11">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Su</surname>
                      <given-names>ZT</given-names>
                    </name>
                    <name>
                      <surname>Segal</surname>
                      <given-names>JB</given-names>
                    </name>
                    <name>
                      <surname>Lanzkron</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Ogunsile</surname>
                      <given-names>FJ</given-names>
                    </name>
                  </person-group>
                  <article-title>National trends in hydroxyurea and opioid prescribing for sickle cell disease by office-based physicians in the United States, 1997-2017</article-title>
                  <source>Pharmacoepidemiol Drug Saf</source>
                  <volume>28</volume>
                  <issue>9</issue>
                  <year>2019</year>
                  <fpage>1246</fpage>
                  <lpage>1250</lpage>
                  <pub-id pub-id-type="pmid">31328369</pub-id>
                </element-citation>
              </ref>
              <ref id="bib12">
                <label>12</label>
                <element-citation publication-type="journal" id="sref12">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kang</surname>
                      <given-names>HA</given-names>
                    </name>
                    <name>
                      <surname>Barner</surname>
                      <given-names>JC</given-names>
                    </name>
                  </person-group>
                  <article-title>The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease</article-title>
                  <source>J Manag Care Spec Pharm</source>
                  <volume>26</volume>
                  <issue>11</issue>
                  <year>2020</year>
                  <fpage>1412</fpage>
                  <lpage>1422</lpage>
                  <pub-id pub-id-type="pmid">33119448</pub-id>
                </element-citation>
              </ref>
              <ref id="bib13">
                <label>13</label>
                <element-citation publication-type="journal" id="sref13">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Candrilli</surname>
                      <given-names>SD</given-names>
                    </name>
                    <name>
                      <surname>O'Brien</surname>
                      <given-names>SH</given-names>
                    </name>
                    <name>
                      <surname>Ware</surname>
                      <given-names>RE</given-names>
                    </name>
                    <name>
                      <surname>Nahata</surname>
                      <given-names>MC</given-names>
                    </name>
                    <name>
                      <surname>Seiber</surname>
                      <given-names>EE</given-names>
                    </name>
                    <name>
                      <surname>Balkrishnan</surname>
                      <given-names>R</given-names>
                    </name>
                  </person-group>
                  <article-title>Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease</article-title>
                  <source>Am J Hematol</source>
                  <volume>86</volume>
                  <issue>3</issue>
                  <year>2011</year>
                  <fpage>273</fpage>
                  <lpage>277</lpage>
                  <pub-id pub-id-type="pmid">21328441</pub-id>
                </element-citation>
              </ref>
              <ref id="bib14">
                <label>14</label>
                <element-citation publication-type="journal" id="sref14">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hankins</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Klesges</surname>
                      <given-names>LM</given-names>
                    </name>
                  </person-group>
                  <article-title>Bridging the implementation gap in medication adherence. If you build it, will they come?</article-title>
                  <source>Br J Haematol</source>
                  <volume>196</volume>
                  <issue>1</issue>
                  <year>2022</year>
                  <fpage>17</fpage>
                  <lpage>18</lpage>
                  <pub-id pub-id-type="pmid">34786706</pub-id>
                </element-citation>
              </ref>
              <ref id="bib15">
                <label>15</label>
                <element-citation publication-type="journal" id="sref15">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Loiselle</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Lee</surname>
                      <given-names>JL</given-names>
                    </name>
                    <name>
                      <surname>Szulczewski</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Drake</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Crosby</surname>
                      <given-names>LE</given-names>
                    </name>
                    <name>
                      <surname>Pai</surname>
                      <given-names>AL</given-names>
                    </name>
                  </person-group>
                  <article-title>Systematic and meta-analytic review: medication adherence among pediatric patients with sickle cell disease</article-title>
                  <source>J Pediatr Psychol</source>
                  <volume>41</volume>
                  <issue>4</issue>
                  <year>2016</year>
                  <fpage>406</fpage>
                  <lpage>418</lpage>
                  <pub-id pub-id-type="pmid">26384715</pub-id>
                </element-citation>
              </ref>
              <ref id="bib16">
                <label>16</label>
                <element-citation publication-type="journal" id="sref16">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Badawy</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Thompson</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Penedo</surname>
                      <given-names>FJ</given-names>
                    </name>
                    <name>
                      <surname>Lai</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Rychlik</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Liem</surname>
                      <given-names>RI</given-names>
                    </name>
                  </person-group>
                  <article-title>Barriers to hydroxyurea adherence and health-related quality of life in adolescents and young adults with sickle cell disease</article-title>
                  <source>Eur J Haematol</source>
                  <volume>98</volume>
                  <issue>6</issue>
                  <year>2017</year>
                  <fpage>608</fpage>
                  <lpage>614</lpage>
                  <pub-id pub-id-type="pmid">28306171</pub-id>
                </element-citation>
              </ref>
              <ref id="bib17">
                <label>17</label>
                <element-citation publication-type="journal" id="sref17">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Walsh</surname>
                      <given-names>KE</given-names>
                    </name>
                    <name>
                      <surname>Cutrona</surname>
                      <given-names>SL</given-names>
                    </name>
                    <name>
                      <surname>Kavanagh</surname>
                      <given-names>PL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Medication adherence among pediatric patients with sickle cell disease: a systematic review</article-title>
                  <source>Pediatrics</source>
                  <volume>134</volume>
                  <issue>6</issue>
                  <year>2014</year>
                  <fpage>1175</fpage>
                  <lpage>1183</lpage>
                  <pub-id pub-id-type="pmid">25404717</pub-id>
                </element-citation>
              </ref>
              <ref id="bib18">
                <label>18</label>
                <element-citation publication-type="journal" id="sref18">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lanzkron</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Strouse</surname>
                      <given-names>JJ</given-names>
                    </name>
                    <name>
                      <surname>Wilson</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Systematic review: hydroxyurea for the treatment of adults with sickle cell disease</article-title>
                  <source>Ann Intern Med</source>
                  <volume>148</volume>
                  <issue>12</issue>
                  <year>2008</year>
                  <fpage>939</fpage>
                  <lpage>955</lpage>
                  <pub-id pub-id-type="pmid">18458272</pub-id>
                </element-citation>
              </ref>
              <ref id="bib19">
                <label>19</label>
                <element-citation publication-type="journal" id="sref19">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Brousseau</surname>
                      <given-names>DC</given-names>
                    </name>
                    <name>
                      <surname>Richardson</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Hall</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Hydroxyurea use for sickle cell disease among Medicaid-enrolled children</article-title>
                  <source>Pediatrics</source>
                  <volume>144</volume>
                  <issue>1</issue>
                  <year>2019</year>
                  <object-id pub-id-type="publisher-id">e20183285</object-id>
                </element-citation>
              </ref>
              <ref id="bib20">
                <label>20</label>
                <element-citation publication-type="journal" id="sref20">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Smeltzer</surname>
                      <given-names>MP</given-names>
                    </name>
                    <name>
                      <surname>Howell</surname>
                      <given-names>KE</given-names>
                    </name>
                    <name>
                      <surname>Treadwell</surname>
                      <given-names>M</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA</article-title>
                  <source>BMJ Open</source>
                  <volume>11</volume>
                  <issue>11</issue>
                  <year>2021</year>
                  <object-id pub-id-type="publisher-id">e050880</object-id>
                </element-citation>
              </ref>
              <ref id="bib21">
                <label>21</label>
                <element-citation publication-type="journal" id="sref21">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Kanter</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Gibson</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Lawrence</surname>
                      <given-names>RH</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Perceptions of US adolescents and adults with sickle cell disease on their quality of care</article-title>
                  <source>JAMA Netw Open</source>
                  <volume>3</volume>
                  <issue>5</issue>
                  <year>2020</year>
                  <object-id pub-id-type="publisher-id">e206016</object-id>
                </element-citation>
              </ref>
              <ref id="bib22">
                <label>22</label>
                <element-citation publication-type="journal" id="sref22">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Alberts</surname>
                      <given-names>NM</given-names>
                    </name>
                    <name>
                      <surname>Badawy</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Hodges</surname>
                      <given-names>J</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Development of the InCharge Health mobile app to improve adherence to hydroxyurea in patients with sickle cell disease: user-centered design approach</article-title>
                  <source>JMIR Mhealth Uhealth</source>
                  <volume>8</volume>
                  <issue>5</issue>
                  <year>2020</year>
                  <object-id pub-id-type="publisher-id">e14884</object-id>
                </element-citation>
              </ref>
              <ref id="bib23">
                <label>23</label>
                <element-citation publication-type="journal" id="sref23">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hodges</surname>
                      <given-names>JR</given-names>
                    </name>
                    <name>
                      <surname>Phillips</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Norell</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study</article-title>
                  <source>Blood Adv</source>
                  <volume>4</volume>
                  <issue>18</issue>
                  <year>2020</year>
                  <fpage>4463</fpage>
                  <lpage>4473</lpage>
                  <pub-id pub-id-type="pmid">32941646</pub-id>
                </element-citation>
              </ref>
              <ref id="bib24">
                <label>24</label>
                <element-citation publication-type="book" id="sref24">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Stretcher</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Rosenstock</surname>
                      <given-names>IM</given-names>
                    </name>
                  </person-group>
                  <part-title>The Health Belief Model</part-title>
                  <person-group person-group-type="editor">
                    <name>
                      <surname>Glanz</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Lewis</surname>
                      <given-names>FM</given-names>
                    </name>
                    <name>
                      <surname>Rimer</surname>
                      <given-names>BK</given-names>
                    </name>
                  </person-group>
                  <source>Health Behaviour and Health Education: Theory, Research and Practice</source>
                  <year>1997</year>
                  <publisher-name>Jossey-Bass</publisher-name>
                </element-citation>
              </ref>
              <ref id="bib25">
                <label>25</label>
                <element-citation publication-type="book" id="sref25">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bandura</surname>
                      <given-names>A</given-names>
                    </name>
                  </person-group>
                  <part-title>Social cognitive theory. Handbook of theories of social psychology</part-title>
                  <volume>Vol 1</volume>
                  <year>2012</year>
                  <publisher-name>Sage Publications Ltd</publisher-name>
                  <fpage>349</fpage>
                  <lpage>373</lpage>
                </element-citation>
              </ref>
              <ref id="bib26">
                <label>26</label>
                <element-citation publication-type="journal" id="sref26">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hankins</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Shah</surname>
                      <given-names>N</given-names>
                    </name>
                    <name>
                      <surname>DiMartino</surname>
                      <given-names>L</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Integration of mobile health into sickle cell disease care to increase hydroxyurea utilization: protocol for an efficacy and implementation study</article-title>
                  <source>JMIR Res Protoc</source>
                  <volume>9</volume>
                  <issue>7</issue>
                  <year>2020</year>
                  <object-id pub-id-type="publisher-id">e16319</object-id>
                </element-citation>
              </ref>
              <ref id="bib27">
                <label>27</label>
                <element-citation publication-type="journal" id="sref27">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bijlsma</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Janssen</surname>
                      <given-names>F</given-names>
                    </name>
                    <name>
                      <surname>Hak</surname>
                      <given-names>E</given-names>
                    </name>
                  </person-group>
                  <article-title>Estimating time-varying drug adherence using electronic records: extending the proportion of days covered (PDC) method</article-title>
                  <source>Pharmacoepidemiol Drug Saf</source>
                  <volume>25</volume>
                  <issue>3</issue>
                  <year>2016</year>
                  <fpage>325</fpage>
                  <lpage>332</lpage>
                  <pub-id pub-id-type="pmid">26687394</pub-id>
                </element-citation>
              </ref>
              <ref id="bib28">
                <label>28</label>
                <element-citation publication-type="other" id="sref28">
                  <article-title>Centers for Medicare and Medicaid Services. 2023 Medicare-Medicaid Plan Performance Data Technical Notes. 2022. Accessed 27 December 2022</article-title>
                  <ext-link ext-link-type="uri" xlink:href="https://www.cms.gov/files/document/mmpperformancedatatechnotes.pdf" id="intref0020">https://www.cms.gov/files/document/mmpperformancedatatechnotes.pdf</ext-link>
                </element-citation>
              </ref>
              <ref id="bib29">
                <label>29</label>
                <element-citation publication-type="journal" id="sref29">
                  <person-group person-group-type="author">
                    <name>
                      <surname>DiMartino</surname>
                      <given-names>LD</given-names>
                    </name>
                    <name>
                      <surname>Baumann</surname>
                      <given-names>AA</given-names>
                    </name>
                    <name>
                      <surname>Hsu</surname>
                      <given-names>LL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>The sickle cell disease implementation consortium: translating evidence-based guidelines into practice for sickle cell disease</article-title>
                  <source>Am J Hematol</source>
                  <volume>93</volume>
                  <issue>12</issue>
                  <year>2018</year>
                  <fpage>E391</fpage>
                  <lpage>E395</lpage>
                  <pub-id pub-id-type="pmid">30203558</pub-id>
                </element-citation>
              </ref>
              <ref id="bib30">
                <label>30</label>
                <element-citation publication-type="book" id="sref30">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Bosworth</surname>
                      <given-names>HB</given-names>
                    </name>
                  </person-group>
                  <part-title>Enhancing Medication Adherence: The Public Health Dilemma</part-title>
                  <year>2014</year>
                  <publisher-name>Springer Healthcare Limited</publisher-name>
                </element-citation>
              </ref>
              <ref id="bib31">
                <label>31</label>
                <element-citation publication-type="journal" id="sref31">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Keller</surname>
                      <given-names>SD</given-names>
                    </name>
                    <name>
                      <surname>Yang</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Treadwell</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Werner</surname>
                      <given-names>EM</given-names>
                    </name>
                    <name>
                      <surname>Hassell</surname>
                      <given-names>KL</given-names>
                    </name>
                  </person-group>
                  <article-title>Patient reports of health outcome for adults living with sickle cell disease: development and testing of the ASCQ-Me item banks</article-title>
                  <source>Health Qual Life Outcomes</source>
                  <volume>12</volume>
                  <year>2014</year>
                  <fpage>125</fpage>
                  <pub-id pub-id-type="pmid">25146160</pub-id>
                </element-citation>
              </ref>
              <ref id="bib32">
                <label>32</label>
                <element-citation publication-type="journal" id="sref32">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Keller</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Wilkinson</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Treadwell</surname>
                      <given-names>MJ</given-names>
                    </name>
                    <name>
                      <surname>Hassell</surname>
                      <given-names>KL</given-names>
                    </name>
                  </person-group>
                  <article-title>Sensitivity of alternative measures of functioning and wellbeing for adults with sickle cell disease: comparison of PROMIS(R) to ASCQ-Me<sup>SM</sup></article-title>
                  <source>Int J Pharm Healthc Mark</source>
                  <volume>11</volume>
                  <issue>2</issue>
                  <year>2017</year>
                  <fpage>117</fpage>
                  <lpage>132</lpage>
                  <pub-id pub-id-type="pmid">28824705</pub-id>
                </element-citation>
              </ref>
              <ref id="bib33">
                <label>33</label>
                <element-citation publication-type="journal" id="sref33">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Dampier</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Barry</surname>
                      <given-names>V</given-names>
                    </name>
                    <name>
                      <surname>Gross</surname>
                      <given-names>HE</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Initial evaluation of the pediatric PROMIS(R) health domains in children and adolescents with sickle cell disease</article-title>
                  <source>Pediatr Blood Cancer</source>
                  <volume>63</volume>
                  <issue>6</issue>
                  <year>2016</year>
                  <fpage>1031</fpage>
                  <lpage>1037</lpage>
                  <pub-id pub-id-type="pmid">26895143</pub-id>
                </element-citation>
              </ref>
              <ref id="bib34">
                <label>34</label>
                <element-citation publication-type="journal" id="sref34">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Askew</surname>
                      <given-names>RL</given-names>
                    </name>
                    <name>
                      <surname>Cook</surname>
                      <given-names>KF</given-names>
                    </name>
                    <name>
                      <surname>Keefe</surname>
                      <given-names>FJ</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A PROMIS measure of neuropathic pain quality</article-title>
                  <source>Value Health</source>
                  <volume>19</volume>
                  <issue>5</issue>
                  <year>2016</year>
                  <fpage>623</fpage>
                  <lpage>630</lpage>
                  <pub-id pub-id-type="pmid">27565279</pub-id>
                </element-citation>
              </ref>
              <ref id="bib35">
                <label>35</label>
                <element-citation publication-type="journal" id="sref35">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gruber-Baldini</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Velozo</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Romero</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Shulman</surname>
                      <given-names>LM</given-names>
                    </name>
                  </person-group>
                  <article-title>Validation of the PROMIS((R)) measures of self-efficacy for managing chronic conditions</article-title>
                  <source>Qual Life Res</source>
                  <volume>26</volume>
                  <issue>7</issue>
                  <year>2017</year>
                  <fpage>1915</fpage>
                  <lpage>1924</lpage>
                  <pub-id pub-id-type="pmid">28239781</pub-id>
                </element-citation>
              </ref>
              <ref id="bib36">
                <label>36</label>
                <element-citation publication-type="journal" id="sref36">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Gershon</surname>
                      <given-names>RC</given-names>
                    </name>
                    <name>
                      <surname>Lai</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Bode</surname>
                      <given-names>R</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Neuro-QOL: quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing</article-title>
                  <source>Qual Life Res</source>
                  <volume>21</volume>
                  <issue>3</issue>
                  <year>2012</year>
                  <fpage>475</fpage>
                  <lpage>486</lpage>
                  <pub-id pub-id-type="pmid">21874314</pub-id>
                </element-citation>
              </ref>
              <ref id="bib37">
                <label>37</label>
                <element-citation publication-type="journal" id="sref37">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hankins</surname>
                      <given-names>JS</given-names>
                    </name>
                    <name>
                      <surname>Potter</surname>
                      <given-names>MB</given-names>
                    </name>
                    <name>
                      <surname>Fernandez</surname>
                      <given-names>ME</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Evaluating the implementation of a multi-level mHealth study to improve hydroxyurea utilization in sickle cell disease</article-title>
                  <source>Front Health Serv</source>
                  <volume>2</volume>
                  <year>2023</year>
                  <fpage>2</fpage>
                </element-citation>
              </ref>
              <ref id="bib38">
                <label>38</label>
                <element-citation publication-type="journal" id="sref38">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jeminiwa</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Hohmann</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Qian</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Garza</surname>
                      <given-names>K</given-names>
                    </name>
                    <name>
                      <surname>Hansen</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Fox</surname>
                      <given-names>BI</given-names>
                    </name>
                  </person-group>
                  <article-title>Impact of eHealth on medication adherence among patients with asthma: a systematic review and meta-analysis</article-title>
                  <source>Respir Med</source>
                  <volume>149</volume>
                  <year>2019</year>
                  <fpage>59</fpage>
                  <lpage>68</lpage>
                  <pub-id pub-id-type="pmid">30803887</pub-id>
                </element-citation>
              </ref>
              <ref id="bib39">
                <label>39</label>
                <element-citation publication-type="journal" id="sref39">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Mikulski</surname>
                      <given-names>BS</given-names>
                    </name>
                    <name>
                      <surname>Bellei</surname>
                      <given-names>EA</given-names>
                    </name>
                    <name>
                      <surname>Biduski</surname>
                      <given-names>D</given-names>
                    </name>
                    <name>
                      <surname>De Marchi</surname>
                      <given-names>ACB</given-names>
                    </name>
                  </person-group>
                  <article-title>Mobile health applications and medication adherence of patients with hypertension: a systematic review and meta-analysis</article-title>
                  <source>Am J Prev Med</source>
                  <volume>62</volume>
                  <issue>4</issue>
                  <year>2022</year>
                  <fpage>626</fpage>
                  <lpage>634</lpage>
                  <pub-id pub-id-type="pmid">34963562</pub-id>
                </element-citation>
              </ref>
              <ref id="bib40">
                <label>40</label>
                <element-citation publication-type="journal" id="sref40">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Tian</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Ajay</surname>
                      <given-names>VS</given-names>
                    </name>
                    <name>
                      <surname>Dunzhu</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>A cluster-randomized, controlled trial of a simplified multifaceted management program for individuals at high cardiovascular risk (SimCard Trial) in rural Tibet, China, and Haryana, India</article-title>
                  <source>Circulation</source>
                  <volume>132</volume>
                  <issue>9</issue>
                  <year>2015</year>
                  <fpage>815</fpage>
                  <lpage>824</lpage>
                  <pub-id pub-id-type="pmid">26187183</pub-id>
                </element-citation>
              </ref>
              <ref id="bib41">
                <label>41</label>
                <element-citation publication-type="journal" id="sref41">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Al-Arkee</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Mason</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Lane</surname>
                      <given-names>DA</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Mobile apps to improve medication adherence in cardiovascular disease: systematic review and meta-analysis</article-title>
                  <source>J Med Internet Res</source>
                  <volume>23</volume>
                  <issue>5</issue>
                  <year>2021</year>
                  <object-id pub-id-type="publisher-id">e24190</object-id>
                </element-citation>
              </ref>
              <ref id="bib42">
                <label>42</label>
                <element-citation publication-type="journal" id="sref42">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Thakkar</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Kurup</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Laba</surname>
                      <given-names>TL</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Mobile telephone text messaging for medication adherence in chronic disease: a meta-analysis</article-title>
                  <source>JAMA Intern Med</source>
                  <volume>176</volume>
                  <issue>3</issue>
                  <year>2016</year>
                  <fpage>340</fpage>
                  <lpage>349</lpage>
                  <pub-id pub-id-type="pmid">26831740</pub-id>
                </element-citation>
              </ref>
              <ref id="bib43">
                <label>43</label>
                <element-citation publication-type="journal" id="sref43">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Feng</surname>
                      <given-names>R</given-names>
                    </name>
                    <name>
                      <surname>Mayuranathan</surname>
                      <given-names>T</given-names>
                    </name>
                    <name>
                      <surname>Huang</surname>
                      <given-names>P</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Activation of gamma-globin expression by hypoxia-inducible factor 1alpha</article-title>
                  <source>Nature</source>
                  <volume>610</volume>
                  <issue>7933</issue>
                  <year>2022</year>
                  <fpage>783</fpage>
                  <lpage>790</lpage>
                  <pub-id pub-id-type="pmid">36224385</pub-id>
                </element-citation>
              </ref>
              <ref id="bib44">
                <label>44</label>
                <element-citation publication-type="journal" id="sref44">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Badawy</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>DiMartino</surname>
                      <given-names>L</given-names>
                    </name>
                    <name>
                      <surname>Brambilla</surname>
                      <given-names>D</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Impact of the COVID-19 pandemic on the implementation of mobile health to improve the uptake of hydroxyurea in patients with sickle cell disease: mixed methods study</article-title>
                  <source>JMIR Form Res</source>
                  <volume>6</volume>
                  <issue>10</issue>
                  <year>2022</year>
                  <object-id pub-id-type="publisher-id">e41415</object-id>
                </element-citation>
              </ref>
              <ref id="bib45">
                <label>45</label>
                <element-citation publication-type="journal" id="sref45">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Naar</surname>
                      <given-names>S</given-names>
                    </name>
                    <name>
                      <surname>Robles</surname>
                      <given-names>G</given-names>
                    </name>
                    <name>
                      <surname>MacDonell</surname>
                      <given-names>KK</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Comparative effectiveness of community-based vs clinic-based healthy choices motivational intervention to improve health behaviors among youth living with HIV: a randomized clinical trial</article-title>
                  <source>JAMA Netw Open</source>
                  <volume>3</volume>
                  <issue>8</issue>
                  <year>2020</year>
                  <object-id pub-id-type="publisher-id">e2014650</object-id>
                </element-citation>
              </ref>
              <ref id="bib46">
                <label>46</label>
                <element-citation publication-type="journal" id="sref46">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Papus</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Dima</surname>
                      <given-names>AL</given-names>
                    </name>
                    <name>
                      <surname>Viprey</surname>
                      <given-names>M</given-names>
                    </name>
                    <name>
                      <surname>Schott</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Schneider</surname>
                      <given-names>MP</given-names>
                    </name>
                    <name>
                      <surname>Novais</surname>
                      <given-names>T</given-names>
                    </name>
                  </person-group>
                  <article-title>Motivational interviewing to support medication adherence in adults with chronic conditions: systematic review of randomized controlled trials</article-title>
                  <source>Patient Educ Couns</source>
                  <volume>105</volume>
                  <issue>11</issue>
                  <year>2022</year>
                  <fpage>3186</fpage>
                  <lpage>3203</lpage>
                  <pub-id pub-id-type="pmid">35779984</pub-id>
                </element-citation>
              </ref>
              <ref id="bib47">
                <label>47</label>
                <element-citation publication-type="journal" id="sref47">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Jonassaint</surname>
                      <given-names>CR</given-names>
                    </name>
                    <name>
                      <surname>Kang</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Abrams</surname>
                      <given-names>DM</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Understanding patterns and correlates of daily pain using the sickle cell disease mobile application to record symptoms via technology (SMART)</article-title>
                  <source>Br J Haematol</source>
                  <volume>183</volume>
                  <issue>2</issue>
                  <year>2018</year>
                  <fpage>306</fpage>
                  <lpage>308</lpage>
                  <pub-id pub-id-type="pmid">29076140</pub-id>
                </element-citation>
              </ref>
              <ref id="bib48">
                <label>48</label>
                <element-citation publication-type="journal" id="sref48">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Hood</surname>
                      <given-names>AM</given-names>
                    </name>
                    <name>
                      <surname>Nwankwo</surname>
                      <given-names>C</given-names>
                    </name>
                    <name>
                      <surname>Walton</surname>
                      <given-names>A</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Mobile health use predicts self-efficacy and self-management in adolescents with sickle cell disease</article-title>
                  <source>Transl Behav Med</source>
                  <volume>11</volume>
                  <issue>10</issue>
                  <year>2021</year>
                  <fpage>1823</fpage>
                  <lpage>1831</lpage>
                  <pub-id pub-id-type="pmid">33949674</pub-id>
                </element-citation>
              </ref>
              <ref id="bib49">
                <label>49</label>
                <element-citation publication-type="journal" id="sref49">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Nahum-Shani</surname>
                      <given-names>I</given-names>
                    </name>
                    <name>
                      <surname>Shaw</surname>
                      <given-names>SD</given-names>
                    </name>
                    <name>
                      <surname>Carpenter</surname>
                      <given-names>SM</given-names>
                    </name>
                    <name>
                      <surname>Murphy</surname>
                      <given-names>SA</given-names>
                    </name>
                    <name>
                      <surname>Yoon</surname>
                      <given-names>C</given-names>
                    </name>
                  </person-group>
                  <article-title>Engagement in digital interventions</article-title>
                  <source>Am Psychol</source>
                  <volume>77</volume>
                  <issue>7</issue>
                  <year>2022</year>
                  <fpage>836</fpage>
                  <lpage>852</lpage>
                  <pub-id pub-id-type="pmid">35298199</pub-id>
                </element-citation>
              </ref>
              <ref id="bib50">
                <label>50</label>
                <element-citation publication-type="journal" id="sref50">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Torous</surname>
                      <given-names>J</given-names>
                    </name>
                    <name>
                      <surname>Michalak</surname>
                      <given-names>EE</given-names>
                    </name>
                    <name>
                      <surname>O'Brien</surname>
                      <given-names>HL</given-names>
                    </name>
                  </person-group>
                  <article-title>Digital health and engagement-looking behind the measures and methods</article-title>
                  <source>JAMA Netw Open</source>
                  <volume>3</volume>
                  <issue>7</issue>
                  <year>2020</year>
                  <object-id pub-id-type="publisher-id">e2010918</object-id>
                </element-citation>
              </ref>
              <ref id="bib51">
                <label>51</label>
                <element-citation publication-type="journal" id="sref51">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Lamont</surname>
                      <given-names>AE</given-names>
                    </name>
                    <name>
                      <surname>Hsu</surname>
                      <given-names>LL</given-names>
                    </name>
                    <name>
                      <surname>Jacobs</surname>
                      <given-names>S</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>What does it mean to be affiliated with care?: Delphi consensus on the definition of "unaffiliation" and "specialist" in sickle cell disease</article-title>
                  <source>PLoS One</source>
                  <volume>17</volume>
                  <issue>11</issue>
                  <year>2022</year>
                  <object-id pub-id-type="publisher-id">e0272204</object-id>
                </element-citation>
              </ref>
              <ref id="bib52">
                <label>52</label>
                <element-citation publication-type="book" id="sref52">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Shadish</surname>
                      <given-names>WR</given-names>
                    </name>
                    <name>
                      <surname>Cook</surname>
                      <given-names>TD</given-names>
                    </name>
                    <name>
                      <surname>Campbell</surname>
                      <given-names>DT</given-names>
                    </name>
                  </person-group>
                  <part-title>Experimental and quasi-experimental designs for generalized causal inference</part-title>
                  <year>2002</year>
                  <publisher-name>Houghton, Mifflin and Company</publisher-name>
                </element-citation>
              </ref>
              <ref id="bib53">
                <label>53</label>
                <element-citation publication-type="journal" id="sref53">
                  <person-group person-group-type="author">
                    <name>
                      <surname>Longoria</surname>
                      <given-names>JN</given-names>
                    </name>
                    <name>
                      <surname>Pugh</surname>
                      <given-names>NL</given-names>
                    </name>
                    <name>
                      <surname>Gordeuk</surname>
                      <given-names>V</given-names>
                    </name>
                    <etal/>
                  </person-group>
                  <article-title>Patient-reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease</article-title>
                  <source>Am J Hematol</source>
                  <volume>96</volume>
                  <issue>11</issue>
                  <year>2021</year>
                  <fpage>1396</fpage>
                  <lpage>1406</lpage>
                  <pub-id pub-id-type="pmid">34350622</pub-id>
                </element-citation>
              </ref>
            </ref-list>
            <sec id="appsec1" sec-type="supplementary-material">
              <title>Supplementary Material</title>
              <p id="p0575">
                <supplementary-material content-type="local-data" id="ec1">
                  <caption>
                    <title>Supplemental Tables</title>
                  </caption>
                  <media xlink:href="BLOODA_ADV-2023-010670-mmc1.pdf"/>
                </supplementary-material>
              </p>
            </sec>
            <ack id="ack0010">
              <title>Acknowledgments</title>
              <p id="p0560">The authors thank all the study coordinators, research personnel, and patients and their families who participated in this research study. The authors also thank Keith Perry and Jeff Frey for their support with the design of the InCharge Health app. The InCharge Health app was developed by Agency 39a, and the HU Toolbox by SickleSoft.</p>
              <p id="p0560a">The Sickle Cell Disease Implementation Consortium was supported by <funding-source id="gs1">US Federal Government</funding-source> cooperative agreements U24HL133948, U01HL133964, U01HL133990, U01HL133996, U01HL133994, U01HL133997, U01HL134004, U01HL134007, and U01HL134042 from the National Heart Lung and Blood Institute and the National Institute on Minority Health and Health Disparities (Bethesda, MD). This work was also funded by the <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/100001422</institution-id><institution>American Society of Hematology</institution></institution-wrap></funding-source> Bridge Grant. S.M.B. received research support from K23HL150232 during the conduct of this study. L.M.K. received research support from the <funding-source id="gs3"><institution-wrap><institution-id institution-id-type="doi">10.13039/100007737</institution-id><institution>St. Jude Children's Research Hospital</institution></institution-wrap></funding-source>–<funding-source id="gs4">Washington University St. Louis Implementation Sciences Collaborative</funding-source>.</p>
              <sec id="sec6">
                <title>Authorship</title>
                <p id="p0565">Contribution: J.S.H. and N.S. contributed in study concept, enrollment of participants, and manuscript writing; M.B.P., A.K., R.G., V.R.G., J.S., R.L., L.D., S.J., M.E.F., H.B.B., and L.M.K. contributed in study concept, enrollment of participants, and manuscript editing; A.A.K., A.A.B., C.M., L.L.H., C.N., J.S.P., N.M.A., S.M.B., and J.A.G. enrolled participants and revised the manuscript; and D.B. conducted the statistical analysis.</p>
              </sec>
            </ack>
            <fn-group>
              <fn id="d35e874">
                <p id="ntpara0010">Original data are available in BioLINCC. For deidentified participant data access, please refer to the instructions at <ext-link ext-link-type="uri" xlink:href="https://biolincc.nhlbi.nih.gov/home/" id="intref0010">https://biolincc.nhlbi.nih.gov/home/</ext-link>.</p>
              </fn>
              <fn id="d35e880">
                <p id="ntpara0020a">The full-text version of this article contains a data supplement.</p>
              </fn>
            </fn-group>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
